Method for inferring coagulation time extension factor
By measuring the differences and ratios of the specific points of the solidification reaction curve, the factors of solidification time extension are quickly inferred, and the time-consuming and complexity of the determination of solidification time extension in the prior art is solved, and the rapid and simple determination of the factor of solidification time extension is achieved.
Patent Information
- Application Number
- CN202380029962.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-01
- Filing Date
- 2023-03-23
- Publication Date
- 2024-11-15
AI Technical Summary
In existing coagulation examinations, determining factors when coagulation time is prolonged is troublesome and time-consuming. Especially when the specimen does not suspect that heparin contains, the cross-mix test requires long-term incubation and calculation of differential parameters of the coagulation reaction curve, which cannot be quickly Accurately determine the factors that extend the solidification time.
By measuring the coagulation reaction curves of the blood sample being examined, normal blood sample and mixed sample, Tm(X) and Tn(X) were calculated, and the coagulation time prolonging factors were inferred based on the differences between Ts(X) and Tm(X) were used to determine the coagulation time prolonging factor based on the differences between Ts(X) and Tm(X). , using index Rj to compare with threshold, it is inferred that lupus anticoagulant, coagulation factor deficiency or coagulation factor inhibitor is positive.
It is possible to quickly and easily infer coagulation time extension factors without long-term incubation and calculating the differential of the coagulation reaction curve, which improves diagnostic efficiency and accuracy.
Smart Images

Figure BDA0005057252200000341 
Figure BDA0005057252200000391 
Figure BDA0005057252200000411
Abstract
Description
Technical Field
[0001] The invention relates to a method for inferring a factor for prolonging coagulation time. Background Art
[0002] Coagulation test is a test for diagnosing the patient's coagulation ability by adding a prescribed reagent to the patient's blood sample and measuring the coagulation time, etc. Typical examples of coagulation time include prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time, etc. Abnormal coagulation ability leads to prolonged coagulation time. As the reasons for the prolonged coagulation time, the influence of anticoagulants, the reduction of components involved in coagulation, the lack of innate coagulation factors, the acquired expression of autoantibodies that hinder the coagulation reaction, etc. can be cited.
[0003] In the past, when a prolonged coagulation time was found in a coagulation test, a cross-mixing test was generally performed to determine the factor that prolonged the coagulation time when there was no suspicion that the sample contained heparin. In the cross-mixing test, the APTT (immediate reaction) of the blood sample and the normal sample just mixed and the APTT (delayed reaction) after incubation at 37°C for 2 hours were measured, and based on the patterns of the immediate reaction and the delayed reaction, it was determined whether the APTT prolonged factor was due to a coagulation factor inhibitor (anticoagulant), lupus anticoagulant (LA), or a coagulation factor deficiency such as hemophilia. However, the previous cross-mixing test was very cumbersome and time-consuming as described above.
[0004] Patent document 1 describes a method for obtaining information on the cause of prolonged coagulation time, the method comprising: a step of obtaining the first, second, and third coagulation times of a test blood sample, a normal blood sample, and a mixed sample of the test blood sample, a step of obtaining the fourth, fifth, and sixth coagulation times of the test blood sample, the normal blood sample, and the mixed sample after incubating the test blood sample, the normal blood sample, and the mixed sample at a predetermined temperature for 45 minutes to 4 hours, a step of obtaining a first quantitative index based on the first, second, and third coagulation times, a step of obtaining a second quantitative index based on the fourth, fifth, and sixth coagulation times, and a step of obtaining a ratio or difference between the value of the first quantitative index and the value of the second quantitative index, or a value obtained by combining the ratio and the difference; the value is information indicating whether the test blood sample is suspected of containing a coagulation factor inhibitor. However, this method requires incubating the blood sample for a long time.
[0005] Patent document 2 describes a method for determining a blood sample, which includes: a step of preparing mixed plasma by mixing test plasma and normal plasma, a step of obtaining a parameter related to the differential of the coagulation waveform of the mixed plasma, and a step of determining whether the test plasma is suspected to be plasma lacking coagulation factors, or whether it is suspected to be plasma containing lupus anticoagulant (LA) or a coagulation factor inhibitor based on the value of the obtained parameter.
[0006] Prior art literature
[0007] Patent Literature
[0008] Patent Document 1: Japanese Patent No. 6696963
[0009] Patent Document 2: Japanese Patent No. 6871673 Summary of the invention
[0010] The present invention provides a faster and simpler method for estimating a factor that prolongs the coagulation time of a blood sample.
[0011] That is, the present invention provides the following solutions.
[0012] [1] A method for inferring a factor for prolonging coagulation time comprises the following steps:
[0013] 1) Get Tm(X) and Tn(X),
[0014] 2) Infer the factors that prolong the coagulation time of the specimen S based on Tm(X),
[0015] in,
[0016] Tm(X) represents the measurement point or time at which the coagulation reaction curve of the specimen M reaches X% of the coagulation reaction end point Em.
[0017] Tn(X) represents the measurement point or time at which the coagulation reaction curve of the specimen N reaches X% of the coagulation reaction end point En,
[0018] Em is the coagulation reaction end point in the coagulation reaction curve of the specimen M,
[0019] En is the coagulation reaction end point in the coagulation reaction curve of specimen N,
[0020] The sample S is a blood sample with a prolonged coagulation time.
[0021] The sample N is a normal blood sample.
[0022] The sample M is a mixed sample of the sample S and the sample N.
[0023] X is greater than 0 and less than 100.
[0024] [2] The method according to [1], wherein the step 1) further comprises the following steps: detecting a coagulation reaction end point Es in the coagulation reaction curve of the sample S, and obtaining Ts(X) based on Es;
[0025] Ts(X) represents the measurement point or time at which the coagulation reaction curve of the sample S reaches X% of Es.
[0026] [3] The method according to [1] or [2], wherein the above 2) comprises the following steps:
[0027] (i) a step of calculating one or more indices Rj (where j ≥ 1, the indices Rj are calculated based on at least one selected from Ts(X), Tm(X) and Tn(X), and at least one of the indices Rj is calculated based on at least Tm(X));
[0028] (ii) a step of comparing the index Rj with a threshold value Tj;
[0029] (iii) a step of estimating a factor that prolongs the coagulation time of the sample S based on the comparison result,
[0030] The factors that prolong the clotting time include positive lupus anticoagulant, coagulation factor deficiency, or positive coagulation factor inhibitor.
[0031] [4] The method according to [1] or [2], wherein the above 2) comprises the following steps:
[0032] Calculate at least one index selected from the following R1 to R8,
[0033] R1 is an index reflecting the ratio between the difference between Tm(X) and Tn(X) and the difference between Ts(X) and Tn(X) under a specific X.
[0034] R2 is an index that indicates the amount of change in R1(X) within a specific X range.
[0035] R3 is an index reflecting the ratio of the change in Tm(X) to the change in Tn(X) in a specific X range.
[0036] R4 is an index reflecting the relative change rate of T(X) of the sample S or the sample M in a specific range of X.
[0037] R5 is an index reflecting the change in Tm(X) within a specific X range.
[0038] R6 is an index reflecting the difference in Tm(X) between the samples M having different mixing ratios of the sample S and the sample N.
[0039] R7 is an index reflecting the ratio of Tm(X) to Tn(X) at a specific X.
[0040] R8 is an index indicating the amount of change of R7(X) in a specific X range;
[0041] The factor that prolongs the coagulation time of the sample S is estimated using the calculated index.
[0042] [5] The method according to [2], wherein the above 2) comprises the following steps:
[0043] Calculate the following indicators,
[0044] R1(Xa)=[(Tm(Xa)-Tn(Xa)) / (Ts(Xa)-Tn(Xa))]
[0045] (Here, Xa = 5 to 100);
[0046] When R1(Xa) is higher than the threshold value T1, the sample S is estimated to be lupus anticoagulant-positive, and in other cases, the sample S is estimated to be coagulation factor-deficient or coagulation factor inhibitor-positive.
[0047] [6] The method according to [2], wherein the above 2) comprises the following steps:
[0048] Calculate the following indicators,
[0049] R4s(Xx,Xy,Xz)=[(Ts(Xx)-Ts(Xy)) / Ts(Xz)]
[0050] R4m(Xx,Xy,Xz)=[(Tm(Xx)-Tm(Xy)) / Tm(Xz)]
[0051] (Here, Xx=5-30, Xy=10-95 and Xz=5-95, or, Xx=45-70, Xy=10-45 and Xz=5-95, and Xx≠Xy);
[0052] A threshold value T4s for R4s and a threshold value T4m for R4m are set. When R4s of the sample S is lower than the threshold value T4s and R4m is higher than the threshold value T4m, the sample S is estimated to be positive for lupus anticoagulant.
[0053] [7] The method according to [5] or [6], comprising the following steps:
[0054] For the above specimen S which was not inferred to be lupus anticoagulant-positive, the following indexes were calculated:
[0055] R2(Xb,Xc)=[R1(Xb)-R1(Xc)],
[0056] (Here, Xb = 5 to 55, Xc = 10 to 95, Xb ≠ Xc);
[0057] If R2(Xb, Xc) is higher than the threshold value T2, the sample S is inferred to be positive for the coagulation factor inhibitor, and if R2(Xb, Xc) is lower than the threshold value T2, the sample S is inferred to be deficient in the coagulation factor.
[0058] [8] The method according to [7], comprising the following steps:
[0059] For the above-mentioned sample S estimated to be deficient in coagulation factors, the following indexes were calculated:
[0060] R3(Xd,Xe)=[Tm(Xd)-Tm(Xe)] / [Tn(Xd)-Tn(Xe)]
[0061] (Here, Xd=5~90, Xe=10~95, Xe-Xd≥5);
[0062] If R3(Xd, Xe) is lower than the threshold value T3, the sample S is inferred to be positive for the coagulation factor inhibitor.
[0063] [9] The method according to [7], comprising the following steps:
[0064] For the above-mentioned sample S estimated to be deficient in coagulation factors, when the index R3 (Xd, Xe) is lower than the threshold value T3L, the sample S is estimated to be positive for the coagulation factor inhibitor, and
[0065] For the sample S inferred to be positive for the coagulation factor inhibitor, when R3(Xd, Xe) is higher than the threshold value T3H, the sample S is inferred to be a coagulation factor inhibitor-positive sample with a high inhibitor titer. For the sample S inferred to be positive for the coagulation factor inhibitor, when R3(Xd, Xe) is between the threshold values T3L and T3H, the sample S is inferred to be a coagulation factor inhibitor-positive sample with an intermediate inhibitor titer.
[0066] here,
[0067] R3 (Xd, Xe) = [Tm (Xd) - Tm (Xe)] / [ Tn (
[0068] T3L<T3H.
[0069]
[10] The method according to [7], comprising the following steps:
[0070] For the above-mentioned sample S estimated to be positive for the coagulation factor inhibitor, the following indexes were calculated:
[0071] R1(Xa')=[(Tm(Xa')-Tn(Xa')) / (Ts(Xa')-Tn(Xa'))] (here, Xa'=5~80);
[0072] When R1(Xa') is higher than the threshold value T1', the sample S is estimated to be a coagulation factor inhibitor-positive sample having a high inhibitor titer.
[0073]
[11] The method according to [5] or [6], comprising the following steps:
[0074] For the above specimen S which was not inferred to be lupus anticoagulant-positive, the following indexes were calculated:
[0075] R5(Xb,Xc)=[Tm(Xc)-Tm(Xb)]
[0076] (Here, Xb=5-35, Xc=20-95, Xb<Xc);
[0077] When R5(Xb, Xc) is higher than the threshold value T5L and lower than the threshold value T5H (here, T5L<T5H), the sample S is estimated to be deficient in coagulation factors, and otherwise, the sample S is estimated to be positive for coagulation factor inhibitors.
[0078]
[12] The method according to
[11] includes the following steps: for the above-mentioned sample S inferred to be positive for coagulation factor inhibitors, when R5(Xb, Xc) is lower than the threshold value T5L, the sample S is inferred to be a positive sample for coagulation factor inhibitors with a low inhibitor titer; or, for the above-mentioned sample S inferred to be positive for coagulation factor inhibitors, when R5(Xb, Xc) is higher than the threshold value T5H, the sample S is inferred to be a positive sample for coagulation factor inhibitors with a higher inhibitor titer.
[0079]
[13] The method according to [5] or [6], comprising the step of calculating the following index for the sample S that is not inferred to be lupus anticoagulant positive:
[0080] R7(Xb)=[Tm(Xb) / Tn(Xb)]
[0081] R7(Xb')=[Tm(Xb') / Tn(Xb')]
[0082] R8(Xb,Xb')=[R7(Xb)-R7(Xb')]
[0083] (Here, Xb=5-95, Xb'=5-95, Xb≠Xb');
[0084] When R7(Xb) is lower than threshold T7 and R7(Xb') is lower than threshold T7', the sample S is estimated to be deficient in coagulation factors, and when R8(Xb, Xb') is higher than threshold T8, the sample S is estimated to be positive for coagulation factor inhibitors.
[0085]
[14] The method according to [5] or [6], further comprising the following steps:
[0086] For the above sample S which was not concluded to be positive for lupus anticoagulant, Tm A (X) and Tm B (X)(Here, Tm A (X) represents the measurement point or time when the coagulation reaction curve of the mixed sample A reaches X% of the coagulation reaction end point Em, Tm B (X) represents the measurement point or time at which the coagulation reaction curve of the mixed specimen B reaches X% of the coagulation reaction end point Em, the mixed specimen A is a mixed specimen in which the volume ratio of the above specimen S to the above specimen N is 9:1, and the mixed specimen B is a mixed specimen in which the volume ratio of the above specimen S to the above specimen N is 1:9, and X is greater than 0 and less than 100);
[0087] Calculate the following indicators:
[0088] R6(Xb)=[Tm A (Xb)-Tm B (Xb)]
[0089] (Here Xb = 35-95);
[0090] When R6(Xb) is lower than the threshold value T6, the sample S is estimated to be deficient in coagulation factors, and when R6(Xb) is higher than the threshold value T6, the sample S is estimated to be positive for coagulation factor inhibitors.
[0091]
[15] The method according to
[14] , comprising the following step: for the above-mentioned sample S inferred to be positive for coagulation factor inhibitor, when R6(Xb) is higher than threshold value T6', the sample S is inferred to be a coagulation factor inhibitor positive sample with high inhibitor titer.
[0092]
[16] A program for implementing the method described in [1] or [2].
[0093]
[17] An apparatus for implementing the method described in [1] or [2].
[0094] According to the method of the present invention, the factor prolonging the coagulation time of the blood sample can be estimated without incubating the blood sample for a long time as in the conventional cross-mixing test and without calculating the parameter related to the differential of the coagulation reaction curve. The method of the present invention can estimate the factor prolonging the coagulation time of the blood sample more quickly and simply. BRIEF DESCRIPTION OF THE DRAWINGS
[0095] Figure 1 This is an example of a coagulation reaction curve.
[0096] Figure 2 The times when the coagulation reaction reaches 10%, 50%, and 90% of the coagulation reaction end point E on the coagulation reaction curve are represented by T(10), T(50), and T(90), respectively.
[0097] Figure 3 The coagulation reaction curves and T(X) of the specimens under test for different specimen types are shown below. A: LA, B: Def, C: Inh. The upper graph shows the coagulation reaction curve (vertical axis: scattered light amount), and the lower graph shows T(X). Each graph also shows the data of normal specimens (dashed line).
[0098] Figure 4 The coagulation reaction curve and T(X) of the mixed specimen. A, B and C represent the 1:1 mixed specimen of LA, Def and Inh and the normal specimen respectively. The upper figure shows the coagulation reaction curve (vertical axis: scattered light amount), and the lower figure shows T(X). The data of the normal specimen (dashed line) are also shown in each figure.
[0099] Figure 5 A represents APTT for each sample type, B represents the APTT difference before and after heating of a 1:1 mixed sample with a normal sample, and C represents the APTT difference before and after heating of a mixed sample derived from Inh, plotted against the inhibitor titer. Figure 5 A also shows the data of normal samples (NP).
[0100] Figure 6 The following are coagulation reaction curves of the test specimens and mixed specimens. A represents three test specimens (LA, Def, and Inh) with the same APTT (around 100 seconds), and B represents a 1:1 mixed specimen of the test specimen and a normal specimen (LA-M11, Def-M11, and Inh-M11). The data of the normal specimen (NP) are also shown in each figure.
[0101] Figure 7 yes Figure 6Ts(X) and Tm(X) of the specimens shown in . A represents LA and LA-M11, B represents Def and Def-M11, and C represents Inh and Inh-M11. Each figure also shows the data Tn(X) of the normal specimen (NP).
[0102] Figure 8 FT1(X) is calculated for mixed samples. A, B and C show the data of mixed samples with the ratio of tested sample to normal sample being 1:9, 1:1 and 9:1 respectively. In each figure, the single-dotted line represents the mixed sample from LA, the double-dotted line represents the mixed sample from Def, and the solid line represents the mixed sample from Inh.
[0103] Fig. 9 This is [FT1(X)-FT1(95)] calculated for the mixed sample. Figure 8 same.
[0104] Fig.10 A, [FT1(X)-FT1(95)], B, FT2(X), and C, FT3(X, 95) were calculated for the 1:1 mixed sample. In each figure, the double-dashed line represents the mixed sample from Def, and the solid line and the long dashed line represent the mixed sample from Inh with inhibitor titers of 18 and 5, respectively.
[0105] Fig.11 A, i.e., FT1(95) as index 1, B, i.e., FT1(10) as index 2, C, i.e., [FT1(10)-FT1(95)] as index 3, and D, i.e., index 3 for Inh, calculated in Example 4.1) are plotted against the inhibitor titer. A 1:1 mixed sample is used for the calculation of Tm(X).
[0106] Fig.12 A, FT3 (10, 95) as the index 3 for Def and Inh and B, index 3 for Inh, calculated in Example 4.2) are plotted against the inhibitor titer. A 1:1 mixed sample was used for the calculation of Tm(X).
[0107] Fig.13 A, FT1(10) as index 1, B, FT3(10,85) as index 2, and C, index 2 for Inh, calculated in Example 4.4) are plotted against the inhibitor titer. A 9:1 mixed sample was used for the calculation of Tm(X).
[0108] Fig.14A, i.e., FT1(95) as index 1, B, i.e., FT1(10) as index 2, C, i.e., [FT1(10)-FT1(95)] as index 3, D, i.e., FT3(10,95) as index 4, and E, i.e., index 4 for Inh, calculated in Example 4.5) are plotted against the inhibitor titer for the test specimen. A 1:9 mixed specimen was used for the calculation of Tm(X).
[0109] Fig.15 A, i.e., FT4s (5, 35, 50) as index 1, B, i.e., FT4m (5, 35, 50) as index 2, C, i.e., FT5 (5, 35) as index 3, and D, i.e., index 3 for Inh, calculated in Example 5.1) are plotted against the inhibitor titer for the test specimen. A 1:1 mixed specimen is used for the calculation of Tm(X).
[0110] Fig.16 A, i.e., FT1(5) of the mixed sample as index 1, B, i.e., FT6(95) as index 2, and C, i.e., index 2 for Inh, calculated in Example 5.2) are plotted against the inhibitor titer. Tm(X) was calculated using a 9:1 mixed sample for index 1 and a 9:1 and 1:9 mixed sample for index 2.
[0111] Fig.17 A, i.e., FT1(45) as index 1, B, i.e., FT2(45) as index 2, C, i.e., FT2(5) as index 3, D, i.e., FT2(45)-FT2(5) as index 4, and E, i.e., index 4 for Inh, calculated in Example 6, are plotted against the inhibitor titer for the test specimen. A 1:1 mixed specimen was used for the calculation of Tm(X).
[0112] Fig.18 A, Percent Correction (PC), and B, Rosner Index (RI), calculated in Comparative Example 1) for the test specimen, and a graph of PC versus inhibitor titer for Inh, i.e., C, and a graph of RI versus inhibitor titer, i.e., D. A 1:1 mixed specimen was used for the calculation of Tm(X).
[0113] Fig.19 A, the percentage correction (PC), and B, the Rosner index (RI), calculated in Comparative Example 2) for the test specimen, and a graph of PC versus inhibitor titer for Inh, namely C, and a graph of RI versus inhibitor titer, namely D. A 9:1 mixed specimen was used for the calculation of Tm(X).
[0114] Fig. 20A, the percentage correction (PC), and B, the Rosner index (RI), calculated in Comparative Example 3) for the test specimen, and a graph of PC versus inhibitor titer for Inh, namely C, and a graph of RI versus inhibitor titer, namely D. A 1:9 mixed specimen was used for the calculation of Tm(X).
[0115] Fig.21 is an exemplary process for using the method of the present invention to infer factors that prolong clotting time.
[0116] Fig. 22 This is a conceptual diagram showing the configuration of an automatic analysis device for carrying out the method for estimating a factor prolonging coagulation time according to the present invention. DETAILED DESCRIPTION
[0117] In a coagulation test, a prescribed reagent is added to a blood sample and the subsequent coagulation reaction is measured, and the coagulation time is determined from the coagulation reaction. In the following description, the blood sample is sometimes referred to as the sample. The coagulation reaction is measured by general means, such as optical means for measuring the amount of scattered light, transmittance, absorbance, etc., or mechanical means for measuring the viscosity of plasma. The coagulation reaction is generally represented by a coagulation reaction curve that shows the time-dependent change in the amount of coagulation reaction. The coagulation reaction curve based on the amount of scattered light of a normal sample without coagulation abnormalities usually rises sharply at the moment when a certain period of time has passed since the addition of the reagent due to the progress of coagulation, and then reaches a plateau as the coagulation reaction approaches completion (see Figure 1 ). On the other hand, the coagulation reaction curve of an abnormal specimen with a coagulation abnormality factor shows various shapes depending on the abnormal factor, such as a delay in the rise time of the curve and a slow rise. As a result, the coagulation time of the abnormal specimen is prolonged in most cases compared with the normal specimen. The extension of the coagulation time is an indicator of the presence or absence of a coagulation abnormality factor. On the other hand, the type of the coagulation abnormality factor (coagulation time extension factor) of the abnormal specimen cannot be inferred from the coagulation time.
[0118] When the clotting time, such as APTT, is found to be prolonged in the coagulation test, generally, if there is no suspicion that heparin is contained in the blood sample, a cross-mixing test is performed to determine the factor that prolongs the clotting time (hereinafter, also referred to as "prolonging factor"). In detail, it is determined whether the APTT prolongation is caused by a coagulation factor inhibitor (anticoagulant factor), lupus anticoagulant, or coagulation factor deficiency such as hemophilia. In the cross-mixing test, the APTT (immediate reaction) of the normal sample, the test sample, and the mixed sample of the test sample and the normal sample just after mixing and the APTT (delayed reaction) after incubation at 37°C for 2 hours are measured. Based on the patterns of the immediate reaction and the delayed reaction, the APTT prolonging factor is determined. In the above-mentioned general method, if the cross-mixing test is not performed separately from the clotting time measurement, the prolonging factor cannot be determined. However, the cross-mixing test is time-consuming and laborious because it is necessary to measure the immediate reaction of the mixed sample of the test sample and the normal sample, as well as the delayed reaction after 2 hours of incubation. Specifically, in previous cross-mixing tests, when the APTT of the mixed sample is corrected (normalized) in the immediate reaction, the sample being tested is judged to be coagulation factor deficiency (Def) or low-titer coagulation factor inhibitor positive (Inh). On the other hand, when the APTT of the mixed sample is not corrected, it is impossible to determine whether the sample being tested is lupus anticoagulant (LA) or Inh. The extension factor of the sample being tested is determined by matching the result of the delayed reaction with the above. That is, when the APTT of the mixed sample is not corrected in the immediate reaction, the sample being tested is determined to be LA or Inh by comparing the result of the delayed reaction with the result of the immediate reaction. On the other hand, if the APTT of the mixed sample is corrected in the immediate reaction but not corrected in the delayed reaction, it can be determined that the sample being tested is not Def but low-titer Inh. In this way, in previous cross-mixing tests, if both the immediate reaction and the delayed reaction are not performed, the extension factor of APTT cannot be determined. Therefore, the cross-mixing test cannot meet existing clinical needs, for example, in an emergency, the need to determine the extension factor in the shortest possible time from blood collection.
[0119] The above-mentioned Patent Document 1 describes a method for obtaining information on whether a blood sample of a subject contains a coagulation factor inhibitor. However, the method of Patent Document 1 is based on the principle of a cross-mixing test and requires measuring the immediate reaction of a normal sample, a test sample, and a mixed sample, as well as the delayed reaction after a long incubation period, so it still takes time and effort.
[0120] The above-mentioned Patent Document 2 proposes a method for obtaining data related to the extension factor without long-term incubation of the specimen. However, in the method of Patent Document 2, parameters are used to determine the extension factor based on the differential curve of the coagulation reaction curve, namely, the coagulation rate (first-order differential) and the coagulation acceleration (second-order differential). On the other hand, since the coagulation reaction curve does not have a peak shape like a differential curve, it is impossible to obtain parameters based on the peak vertex such as the maximum coagulation rate and the maximum coagulation rate time. In addition to the coagulation time, there has been almost no attempt to extract information about the coagulation reaction from the coagulation reaction curve.
[0121] In the present invention, the long-term incubation of the specimen used in the above-mentioned conventional techniques (such as the delayed reaction of the cross-mixing test) is not performed, and the differential curve (first-order differential or second-order differential) of the coagulation reaction curve is not used. The coagulation time-extending factor of the specimen can be inferred by analyzing the waveform of the coagulation reaction curve itself.
[0122] [Method for estimating factors that prolong solidification time]
[0123] The present invention provides a method for estimating a factor prolonging coagulation time. In the method for estimating a factor prolonging coagulation time of the present invention (hereinafter, also referred to as the method of the present invention), a blood sample with a prolonged coagulation time is used as a test blood sample (hereinafter, also referred to as a test sample), and the prolongation factor of the test sample is estimated.
[0124] In a conventional coagulation test, time series data of the coagulation reaction of the specimen is obtained, and based on the data, a coagulation reaction curve and a coagulation time of the specimen are obtained. A specimen having a coagulation time longer than a normal value (e.g., a standard value determined based on the coagulation time of a normal specimen group) can be selected as a specimen with a prolonged coagulation time and used as a specimen to be tested in the method of the present invention.
[0125] As the blood sample used in the method of the present invention, plasma is preferably used. An anticoagulant commonly used in coagulation tests may be added to the sample. For example, blood is collected using a blood collection tube containing sodium citrate and then centrifuged to obtain plasma.
[0126] In the method of the present invention, the above-mentioned test specimen, a normal blood specimen that does not show prolonged coagulation time (or simply referred to as a normal specimen), and a mixed specimen obtained by mixing the test specimen and the normal specimen are used. As a normal specimen, a pooled specimen obtained by pooling more than one normal specimen group, commercially available normal plasma, etc. can be used. In the preparation of the mixed specimen, the test specimen and the normal specimen are mixed at a prescribed ratio. The mixing ratio of the test specimen and the normal specimen is a volume ratio with the total volume set to 10, as long as it is in the range of test specimen: normal specimen = 1:9 to 9:1, preferably in the range of 4:6 to 6:4, for example 5:5.
[0127] In the method of the present invention, the coagulation reaction of the test specimen, the normal specimen, and the mixed specimen is measured to obtain a coagulation reaction curve. Hereinafter, the test specimen may be referred to as specimen S, the normal specimen may be referred to as specimen N, and the mixed specimen may be referred to as specimen M. In addition, the test specimen, the normal specimen, and the mixed specimen may be collectively referred to as "specimen".
[0128] As the example of the clotting time measured in the present invention, prothrombin time (PT) and activated partial thromboplastin time (APTT) can be enumerated. In the following description, the activated partial thromboplastin time (APTT) is mainly enumerated as the clotting time to illustrate the method of the present invention. The change of the method of the present invention to other clotting times (for example prothrombin time (PT)) can be implemented by those skilled in the art.
[0129] Hereinafter, the method of the present invention will be described.
[0130] 1. Obtaining the coagulation reaction curve
[0131] 1.1. Measurement of coagulation response
[0132] In the measurement of the coagulation reaction, a coagulation time determination reagent is added to the specimen to start the coagulation reaction. The coagulation reaction of the mixed solution containing the reagent and the specimen can be measured. The coagulation time determination reagent used can be arbitrarily selected according to the purpose of the measurement. Various reagents for coagulation time determination are commercially available (for example, APTT reagent COAGPIA APTT-N; manufactured by Sekisui Medical Co., Ltd.). The measurement of the coagulation reaction can be carried out by general means, for example, optical means for measuring the amount of scattered light, transmittance, absorbance, etc., or mechanical means for measuring the viscosity of plasma, etc. In the following description, the method of the present invention is described by taking the measurement of the coagulation reaction based on the amount of scattered light as an example.
[0133] The reaction start time of the coagulation reaction can typically be defined as the time when the coagulation reaction starts by mixing the reagent in the specimen, but other times can also be defined as the reaction start time. The time for continuing the measurement of the coagulation reaction can be, for example, from the time when the specimen and the reagent are mixed for tens of seconds to about 7 minutes. The measurement time can be an arbitrarily determined fixed time, or it can be the time until the end of the coagulation reaction of each specimen is detected. The measurement of the progress of the coagulation reaction can be repeatedly performed at a specified interval within the measurement time interval (photometry in the case of optical detection). For example, measurements can be performed at intervals of 0.1 seconds. The temperature of the reaction solution in the measurement is, for example, 30°C to 40°C under normal conditions, preferably 35°C to 39°C. In addition, the various conditions for measurement can be appropriately set according to the specimen, reagent, measurement method, etc.
[0134] Unlike the method described in the previous cross-mixing test or Patent Document 1, the method of the present invention does not require further preparation of a specimen that has been incubated for a long time at a specified temperature. For example, in the present invention, when measuring the coagulation reaction, it is not necessary to perform a long-term incubation treatment of the specimen before adding the coagulation time determination reagent (such as the first reagent of the APTT determination) as in the delayed reaction of the previous cross-mixing test. In this specification, "long-term incubation treatment" of the specimen refers to an incubation treatment of more than 5 minutes, preferably more than 2 minutes, preferably at 15°C to 40°C, more preferably 30°C to 40°C. In addition, in this specification, "incubation treatment" of the specimen refers to active temperature control using a heater, cooler, thermostat, etc., and does not include passive temperature changes or maintenance caused by placing it at room temperature, etc.
[0135] On the other hand, in the present invention, the specimen for coagulation reaction measurement may be subjected to a preheating treatment of the specimen for coagulation reaction measurement, for example, a heating treatment of 30°C to 40°C for less than 1 minute, before the addition of the coagulation time measuring reagent. Therefore, the specimen for coagulation reaction measurement in the present invention is not subjected to an incubation treatment of 15°C to 40°C for more than 5 minutes, preferably is not subjected to an incubation treatment of 15°C to 40°C for more than 2 minutes, and more preferably is subjected to an incubation treatment of 15°C to 40°C for less than 1 minute. The specimen for coagulation reaction measurement in the present invention may be subjected to a heating process in a coagulation reaction measurement, that is, a heating treatment in which the reaction solution is kept at 30°C to 40°C, after the addition of the coagulation time measuring reagent (prepared into a reaction solution).
[0136] A series of operations in the above-mentioned coagulation reaction measurement can be performed using an automatic analyzer. As an example of an automatic analyzer, a coagulation automatic analyzer CP3000 (manufactured by Sekisui Medical Co., Ltd.) can be cited. Alternatively, a part of the operation can also be performed manually. For example, the specimen preparation can be performed manually, and the subsequent operations are performed using an automatic analyzer.
[0137] The coagulation reaction curve P(i) is obtained by the above-mentioned coagulation reaction measurement. Herein, "i" represents the number of measurement points, or the time from the start of the coagulation reaction (also referred to as time). For example, if the measurement (photometry) interval is 0.1 seconds, it is represented by time = 0.1 × number of measurement points. That is, P(i) can be a function of the number of measurement points or a function of time. In the following description of the present invention, P(i) is sometimes simply referred to as P. In general, the coagulation reaction curve P is produced by removing noise or smoothing the measured values of the coagulation reaction measurement by conventional means, or by performing zero adjustment or relative value conversion of the curve for adjusting the initial value of the reaction as needed. An example of a coagulation reaction curve is shown in Figure 1 . Figure 1 The horizontal axis represents time, and the vertical axis represents the scattered light amount. As time passes, the coagulation reaction of the mixed solution proceeds, so the scattered light amount increases, and reaches a plateau as the coagulation reaction approaches completion.
[0138] As required, in order to calculate the coagulation time, etc., a differential curve thereof, such as a reaction rate curve (first-order differential) or a reaction acceleration curve (second-order differential) can also be obtained from the obtained coagulation reaction curve P. The differential processing of the coagulation reaction curve can be implemented by any method, for example, it can be performed by calculating the average slope value in the interval. In this specification, the first-order differential curve of the reaction rate curve and the second-order differential curve such as the reaction acceleration curve are also referred to as "first-order curve" and "second-order curve", respectively.
[0139] 1.2. Calculation of solidification time
[0140] The coagulation time of the specimen can be calculated based on the coagulation reaction curve P. The coagulation time can be calculated by any method. Examples of methods for calculating the coagulation time include: a method for calculating the time when P(i) reaches N% of the coagulation reaction end point E (described later) as the coagulation time; a method for calculating the time when the primary curve of P reaches N% of its maximum value as the coagulation time; a method for calculating the time when P(i) reaches N% of P(Te) as the coagulation time by taking the time when the ratio of the cumulative value of P(i) within a small time period reaches a specified value as the calculation starting point Te (Japanese Patent Publication No. 6-249855); a method for calculating the time when P(i) reaches N% of P(Te) based on a small time period. A method for calculating the solidification time by the time-dependent change of the cumulative value of P(i) within a time period (see Japanese Patent Application No. 2019-237427); a method for calculating the solidification time based on the weighted average time of the primary curve of P (see Japanese Patent Application No. 2020-039344); a method for calculating the time when P(i) reaches N% of P(Te) by taking the time when the primary curve of P reaches the maximum value and then reaches the specified value as the calculation starting point Te (see Japanese Patent Application No. 2020-068877), etc.
[0141] When the coagulation time calculated for a sample from a subject is greater than a normal value (for example, a standard value determined based on the coagulation time of a normal sample group), it is determined that the coagulation time of the sample is prolonged. The sample with prolonged coagulation time can be used as a sample for the method of the present invention. In the method of the present invention, when it is necessary to infer the coagulation time prolongation factor of the sample with prolonged coagulation time, a mixed sample can be prepared from the sample, and the coagulation reaction curves of the mixed sample and the normal sample can be obtained.
[0142] 2. Detection of the end point of coagulation reaction
[0143] In the method of the present invention, the coagulation reaction end point E of the coagulation reaction curve P of the specimen is detected. The coagulation reaction end point E can be detected based on any reference, such as the time when P reaches a plateau, the time when the primary curve of P decreases to 0 or a certain value after reaching a peak (refer to Japanese Patent Application No. 2020-068877), the earliest point at which the ratio of the cumulative value of P(i) in a small time period is less than a threshold value (for example, 1.001) (refer to International Application No. PCT / JP2020 / 048676 or the embodiments described later). The detection of the coagulation reaction end point E can be performed after obtaining P until a specified measurement time, or the detection of E can be performed in parallel with the acquisition of P, and the acquisition of P is terminated at the moment when E is detected. For example, the steps described in Japanese Patent Application No. 2020-068877 or International Application No. PCT / JP2020 / 048676 can perform the detection of the coagulation reaction end point E in parallel with the acquisition of P (so-called real-time E detection).
[0144] As one embodiment of the method of the present invention, an example of a detection step of the coagulation reaction end point E based on the method described in International Application No. PCT / JP2020 / 048676 is described in detail. The ratio of the cumulative values of P(i) in a small time period is defined as the cumulative ratio Z(i), which is calculated by the following formula:
[0145] Z(i)={P(i+1)+P(i+2)+...+P(i+m)} / {P(i-m)+P(i-m+1)+...+P(i-1)}
[0146] In the above formula, i represents the measurement point number, and m can be appropriately set according to the measurement conditions of the coagulation reaction, the analysis items, etc. For example, when the measurement interval is 0.1 seconds, m=10 to 30. The earliest measurement point or P(i) at the time when Z(i) is less than the threshold value Zs is detected as the coagulation reaction end point E. Zs can be appropriately set according to the analysis item, and is greater than 1 and less than 1.100. For example, in the case of APTT determination, it is preferably less than 1.050, and more preferably Zs is in the range of 1.010 to 1.001. In order to prevent the erroneous detection of E caused by initial reaction abnormalities, it is preferred that the calculation of Z(i) is started after i reaches the specified calculation start point and P(i) reaches a specified value or above. In this step, while measuring the coagulation reaction, P(i) can be obtained in parallel and Z(i) can be calculated to detect E.
[0147] In the method of the present invention, the coagulation reaction end point E of the coagulation reaction curve can be obtained for the test specimen S, the normal specimen N, and the mixed specimen M, respectively. Hereinafter, the coagulation reaction end point in the coagulation reaction curve of the specimen S is referred to as Es, the coagulation reaction end point in the coagulation reaction curve of the specimen N is referred to as En, and the coagulation reaction end point in the coagulation reaction curve of the specimen M is referred to as Em. In the method of the present invention, it is preferred to obtain at least Em and En. It is more preferred to obtain Es, Em, and En. It should be noted that for En, the coagulation reaction of the specimen N can be measured and En can be detected from the obtained coagulation reaction curve, or En can be detected based on the existing coagulation reaction curve of the specimen N, or an existing En can be used.
[0148] 3. Acquisition of T(X)
[0149] T(X) indicating the measurement point or time at which the coagulation reaction curve P(i) of the specimen reaches X% of E can be calculated for each of the specimens S, N, and M. In this specification, P(i) and T(X) of the specimen S are referred to as Ps(i) (or simply Ps) and Ts(X), respectively, P(i) and T(X) of the specimen N are referred to as Pn(i) (or simply Pn) and Tn(X), respectively, and P(i) and T(X) of the specimen M are referred to as Pm(i) (or simply Pm) and Tm(X), respectively. More specifically, Ts(X) indicates the measurement point or time at which the coagulation reaction curve Ps of the specimen S reaches X% of Es, Tn(X) indicates the measurement point or time at which the coagulation reaction curve Pn of the specimen N reaches X% of En, and Tm(X) indicates the measurement point or time at which the coagulation reaction curve Pm of the specimen M reaches X% of Em. On the other hand, T(X) in this specification is used as a general term including Ts(X), Tn(X) and Tm(X), and the description related to T(X) can also be applied to Ts(X), Tn(X) and Tm(X) unless otherwise specified. In this specification and the accompanying drawings, T(X), Ts(X), Tn(X) and Tm(X) are sometimes recorded as "TX", "TsX", "TnX" and "TmX" respectively without the bracket mark of X. In the method of the present invention, it is preferred to obtain at least Tm(X) and Tn(X). It is more preferred to obtain Ts(X), Tm(X) and Tn(X). It should be noted that Tn(X) can measure the coagulation reaction of the specimen N, and En and Tn(X) can be detected based on the obtained coagulation reaction curve, or Tn(X) can be detected based on the existing coagulation reaction curve of the specimen N, or the existing Tn(X) can be used.
[0150] More specifically, T(X) is the number of measurement points or the time from the start of the coagulation reaction (time 0) until P reaches X% of E. That is, the following equation holds true for T(X).
[0151] P(T(X))=E×X%
[0152] Therefore, the following formulae of Ts(X), Tn(X), and Tm(X) are established respectively.
[0153] Ps(Ts(X))=Es×X%
[0154] Pn(Tn(X))=En×X%
[0155] Pm(Tm(X))=Em×X%
[0156] Here, X is greater than 0 and less than 100. Therefore, T(X) can be expressed as a function of the variable X. In the method of the present invention, X is preferably 1 to 100, and more preferably 5 to 95. For example, each X can be a value separated by more than 1 (i.e., the increment of X ≥ 1), or can also be a value separated by more than 5 (i.e., the increment of X ≥ 5). In one example, X is a variable that changes in an increment of 1 in the range of 1 to 100 (i.e., X = {1, 2, 3, ···, 97, 98, 99, 100}). In another example, X is a variable that changes in an increment of 5 in the range of 5 to 95 (i.e., X = {5, 10, 15, ···, 90, 95}).
[0157] Alternatively, T(X) can be expressed as the average value of T(X-K) to T(X+K). In this case, K is preferably smaller than the increment of X. For example, if K=2, T(X) can be expressed as the average value of T(8) to T(12) when X=10, or as the average value of T(13) to T(17) when X=15. Alternatively, T(X) can be expressed as the average value of T(X-K+1) to T(X). For example, if K=5, T(X) can be expressed as the average value of T(6) to T(10) when X=10, or as the average value of T(91) to T(95) when X=95.
[0158] Figure 2 This is a diagram for explaining T(X). In the figure, a coagulation reaction curve showing the points where E is 10% to 90% is shown, and the times when E is 10%, 50%, and 90% are represented as T(10), T(50), and T(90), respectively. The time tE of E is equivalent to T(100). The T(X) curve obtained by plotting T(X) against X is generally as follows Figure 3 , 4 As shown, the value sometimes rises sharply in the region where X is approximately 1 to 5, but rises slowly until X reaches approximately 80, and then rises sharply after X reaches approximately 90.
[0159] 4. Inference of factors that prolong the clotting time using T(X)
[0160] In the method of the present invention, the coagulation time prolonging factor of the test specimen is inferred based on T(X) calculated from the coagulation reaction curve. As shown in the examples described below, in the method of the present invention, by using T(X), it is possible to distinguish lupus anticoagulant-positive specimens (LA), coagulation factor-deficient specimens (Def), and coagulation factor inhibitor-positive specimens (Inh) from test specimens showing a prolonged coagulation time without the need for incubating the specimen for a long time such as the delayed reaction of a cross-mixing test. In the general coagulation reaction measurement in the past, the only parameter related to the evaluation of the coagulation reaction calculated from the coagulation reaction curve was the coagulation time. However, it is difficult to infer the coagulation time prolonging factor from the coagulation time alone. Figure 5 As shown in FIG. 1 , the coagulation time in the specimens with different prolongation factors overlaps, and even if the coagulation time is compared before and after incubation of the mixed specimen, it is more difficult to infer the prolongation factor. In contrast, in the present invention, the shape of the coagulation reaction curve itself is focused on, and T(X) is calculated as an index reflecting it, thereby inferring the prolongation factor.
[0161] As described later Figure 6 As shown in A, the coagulation reaction of a specimen may show different characteristics depending on the type of various coagulation time-extending factors (type of specimen). Figure 6 A represents the coagulation reaction curve P (vertical axis: scattered light amount) of each type of specimen. The coagulation time of the test specimens (LA, Def and Inh) in the figure is around 100 seconds, which is longer than that of the normal specimen (NP). The shape of the coagulation reaction curve P shows different trends depending on the type of specimen. In the normal specimen (NP), the curve rises steeply. There is a tendency for the coagulation factor-deficient specimen (Def) and the coagulation factor inhibitor-positive specimen (Inh) to have a similar shape of P, or the rise of the curve is relatively slow. In the lupus anticoagulant-positive specimen (LA), even if the coagulation time is prolonged, the curve rises steeply. In this way, even for test specimens whose APTT is prolonged to the same extent, the shape of P is different depending on the type of specimen.
[0162] On the other hand, the coagulation reaction of a mixed sample prepared from a sample having a prolonged coagulation time may show a reaction curve different from that of the original sample. Figure 6 B is for Figure 6A graph showing the coagulation reaction curve P (vertical axis: scattered light amount) of the mixed specimen (mixing ratio; specimen: NP = 1:1) of the specimen shown in A. In the mixed specimens (Def-M11 and Inh-M11 in the figure) derived from the coagulation factor inhibitor-positive specimen (Inh) and the coagulation factor-deficient specimen (Def), the shape of the coagulation reaction curve P is close to that of the normal specimen (NP) by supplementing the coagulation factor contained in the normal specimen, and the coagulation time is within the normal range. On the other hand, in the mixed specimen (LA-M11) derived from the lupus anticoagulant-positive specimen (LA), the shape of the coagulation reaction curve P is similar to that of the original specimen ( Figure 6 A's LA) is similar.
[0163] In addition, T(X) also shows different characteristics depending on the type of specimen. Figure 7 A to C are shown for each sample type. Figure 6 A and B are graphs showing Ts(X) and Tm(X) of the test sample and its mixed sample, respectively. Figure 7 A represents lupus anticoagulant-positive specimens (LA) and their mixed specimens (LA-M11), Figure 7 B represents coagulation factor-deficient specimen (Def) and its mixed specimen (Def-M11), Figure 7 C represents a positive sample of a coagulation factor inhibitor (Inh) and a mixed sample (Inh-M11). Each figure also shows Tn (X) of a normal sample (NP). In each figure, the value (time) of the vertical axis when the horizontal axis is X=50 is APTT (=T(50)).
[0164] Depend on Figure 7 It can be seen that the relative configuration of the curves representing Ts(X), Tm(X), and Tn(X) differs depending on the type of specimen, mainly due to the downward shift of Tm(X) (toward the side close to Tn(X)). That is, the downward shift of Tm(X) is smaller in LA and larger in Def and Inh. As a result, the difference between Ts(X) and Tm(X) at any X [Ts(X)-Tm(X)] is smaller in LA and larger in Def and Inh. Therefore, [Ts(X)-Tm(X)] in Def and Inh is larger than that in LA, while the difference between [Ts(X)-Tm(X)] in Def and [Ts(X)-Tm(X)] in Inh is smaller.
[0165] Therefore, in the present invention, the coagulation time prolonging factor of the test specimen can be inferred based on at least Tm(X). In one embodiment, the method of the present invention infers the coagulation time prolonging factor of the test specimen based on the difference between Tn(X) and Tm(X). In one embodiment, the method of the present invention infers the coagulation time prolonging factor of the test specimen based on the difference between Tm(X) and Ts(X) and Tn(X).
[0166] 4.1. Calculation of the indicator R
[0167] In a preferred embodiment, in the method of the present invention, at least Tm(X) is used to calculate an index R for inferring a coagulation time extension factor, and the coagulation time extension factor of the test object is inferred based on the index R. The index R is an index associated with the coagulation reaction information (coagulation characteristics) of the test object calculated using at least Tm(X). In one embodiment, the index R is calculated by using Tm(X) and Tn(X). In another embodiment, the index R is calculated by using Ts(X), Tm(X) and Tn(X). As examples of the index R, R1, R2, R3, R4, R5, R6, R7, R8, and combinations thereof described below are cited. Therefore, in this specification, "index R" includes any one of R1, R2, R3, R4, R5, R6, R7, R8, etc. and a combination of two or more of them.
[0168] In a preferred embodiment, in the method of the present invention, R1, which is an index reflecting the ratio of the difference between Tm(X) and Tn(X) and the difference between Ts(X) and Tn(X) at a specific X, is calculated. In one example, R1 can be represented by the following formula.
[0169] R1(X)=[(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))]
[0170] In this case, X is preferably 5 to 100, more preferably 5 to 95, and further preferably 55 to 95. R1(X) can be expressed as a percentage (%).
[0171] In a preferred embodiment, in the method of the present invention, R2, which is an index representing the amount of change in R1 within a specific range of X, is calculated. Preferably, R2 can be calculated using X 1 , X 2 It is represented by the following formula.
[0172] R2(X 1 , X 2 )=[R1(X 1 )-R1(X 2 )]
[0173] At this time, X 1Preferably, it is 5 to 55, more preferably 5 to 45, and even more preferably 5 to 40. 2 Preferably, it is 10 to 95, more preferably 15 to 95, and further preferably 20 to 95. 1 ≠X 2 . R2(X 1 , X 2 ) can be expressed as a percentage (%).
[0174] In a preferred embodiment, in the method of the present invention, R3, which is an index reflecting the ratio of the change amount of Tm(X) to the change amount of Tn(X) in a specific range of X, is calculated. Preferably, R3 can be calculated using X 1 , X 2 It is represented by the following formula.
[0175] R3(X 1 , X 2 )=[Tm(X 1 )-Tm(X 2 )] / [Tn(X 1 )-Tn(X 2 )]
[0176] At this time, X 1 Preferably, it is 5 to 90, more preferably 50 to 80, X 2 It is preferably 10 to 95, and more preferably 55 to 85. 2 -X 1 ≥5. R3(X 1 , X 2 ) can be expressed as a percentage (%).
[0177] In a preferred embodiment, in the method of the present invention, R4, which is an index reflecting the relative rate of change of T(X) in a specific range of X for the sample S or the sample M, is calculated. Preferably, R4 can be calculated using X 1 , X 2 , X 3 It is represented by the following formula.
[0178] R4(X 1 , X 2 , X 3 )=[(T(X 2 )-T(X 1 )) / T(X 3 )]
[0179] More specifically, R4(X 1 , X 2 , X 3 ) can be calculated for specimen S and specimen M respectively, and can be expressed by the following formulas respectively.
[0180] R4s(X 1 , X 2 , X 3 )=[(Ts(X 2 )-Ts(X 1 )) / Ts(X 3 )]
[0181] R4m(X 1 , X 2 , X 3 )=[(Tm(X 2 )-Tm(X 1 )) / Tm(X 3 )]
[0182] In various types, X 1 Preferably, it is 5 to 30, more preferably 5 to 25, and even more preferably 5 to 20. 2 Preferably, it is 10 to 95, more preferably 25 to 95, and further preferably 25 to 75. 3 Preferably, 5 to 95, or X 1 Preferably, it is 45 to 70, more preferably 50 to 65, X 2 Preferably, it is 10 to 45, more preferably 10 to 35, X 3 Preferably, it is 5 to 95. 1 ≠X 2 , preferably X 1 <X 2 . R4(X 1 , X 2 , X 3 ) can be expressed as a percentage (%).
[0183] In a preferred embodiment, in the method of the present invention, R5, which is an index reflecting the amount of change in Tm(X) in a specific range of X, is calculated. Preferably, R5 can be calculated using X 1 , X 2 It is represented by the following formula.
[0184] R5(X 1 , X 2 )=[Tm(X 2 )-Tm(X 1 )]
[0185] In various types, X 1 Preferably, it is 5 to 35, more preferably 5 to 10, X 2 Preferably, it is 20 to 95, and more preferably, it is 35 to 65. Preferably, X 1 <X 2 . R5(X 1 , X 2 ) can be expressed as a percentage (%).
[0186] In a preferred embodiment, in the method of the present invention, R6 is calculated as an index reflecting the difference in Tm(X) between samples M having different mixing ratios of sample S and sample N. Preferably, R6 can be represented by the following formula.
[0187] R6(X)=[Tm A (X)-Tm B (X)]
[0188] Here, Tm A (X) represents the Tm(X) of the mixed sample A, Tm B (X) represents Tm(X) of mixed specimen B. Mixed specimens A and B have different mixing ratios of test specimen:normal specimen. The mixing ratio of test specimen:normal specimen in mixed specimens A and B is not particularly limited. In a preferred embodiment, the mixing ratio of test specimen:normal specimen in mixed specimen A is 9:1, and the mixing ratio of test specimen:normal specimen in mixed specimen B is 1:9. X is preferably 35 to 95, more preferably 60 to 95, and further preferably 90 to 95.
[0189] In a preferred embodiment, in the method of the present invention, R7, which is an index reflecting the ratio of Tm(X) to Tn(X) at a specific X, is calculated. Preferably, R7 can be represented by the following formula.
[0190] R7(X)=[Tm(X) / Tn(X)]
[0191] In this case, X is preferably 5 to 95, and more preferably 70 to 95. R7(X) can be expressed as a percentage (%).
[0192] In a preferred embodiment, in the method of the present invention, R8, which is an index representing the amount of change of R7(X) in a specific range of X, is calculated. In one example, R8 can be calculated using X 1 , X 2 It is represented by the following formula.
[0193] R8(X 1 , X 2 )=[R7(X 1 )-R7(X 2 )]
[0194] At this time, X 1 Preferably, it is 10 to 95, more preferably 15 to 95, and still more preferably 70 to 95. 2 Preferably, X is 5 to 90. 1 -5≥X 2 R8(X) can be expressed as a percentage (%).
[0195] The above R1(X), R2(X1 , X 2 )、R3(X 1 , X 2 )、R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 ), R6(X), R7(X) and R8(X 1 , X 2 ) can use a specific X or a group of X 1 ~X 2 or X 1 ~X 3 Alternatively, two or more different X or two or more sets of X may be used. 1 ~X 2 or X 1 ~X 3 And calculate multiple R1(X), R2(X 1 , X 2 )、R3(X 1 , X 2 )、R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 ), R6(X), R7(X), or R8(X 1 , X 2 ). At this time, it is also possible to 1 , X 2 )、R3(X 1 , X 2 )、R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 ), R6(X), R7(X) and R8(X 1 , X 2 ) are calculated for any one, two or three of them, and a specific value is calculated for the remaining ones. 1 , X 2 )、R3(X 1 , X 2 )、R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 ), R6(X), R7(X) and R8(X 1 , X2 ) used in the calculation formula 1 ~X 2 and X 1 ~X 3 Each formula is independent of each other. For example, X used in the calculation of R1(X) and X used in the calculation of R6(X) can be the same value or different values. 1 , X 2 ) is used in the calculation of 1 ~X 2 and in R3(X 1 , X 2 ) is used in the calculation of 1 ~X 2 They can be the same value or different values.
[0196] In one example, R1(Xa) and R2(Xb, Xc) can be calculated using Xa, Xb, and Xc (where Xa, Xb, and Xc are the same or different values from each other, and Xb≠Xc).
[0197] In another example, R1(Xa) and R3(Xd, Xe) can be calculated using Xa, Xd, and Xe (where Xa, Xd, and Xe are the same or different values from each other, and Xd≠Xe).
[0198] In another example, Xa, Xa', Xb, Xc, Xd and Xe (here, Xa, Xa', Xb, Xc, Xd and Xe are the same or different values, wherein Xa≠Xa', Xb≠Xc, and Xd≠Xe) can be used to calculate R1(Xa) and at least one selected from R1(Xa'), R2(Xb, Xc) and R3(Xd, Xe). In one example, R1(Xa), R2(Xb, Xc) and R3(Xd, Xe) are calculated. In another example, R1(Xa) and R3(Xd, Xe) are calculated. In another example, R1(Xa), R1(Xa'), R2(Xb, Xc) and R3(Xd, Xe) are calculated. In this case, Xa≠Xa', Xa is preferably 5 to 100, more preferably 5 to 95, and further preferably 55 to 95, and Xa' is preferably 5 to 100, and more preferably 5 to 80. Xb and Xc, as well as Xd and Xe, can be selected from the group consisting of the above R2 (X 1 , X 2 ) related to X 1 and X 2 range, and R3(X 1 , X 2 ) Related X 1 and X 2 Select from the range.
[0199] In another example, Xa and Xa' (here, Xa < Xa') can be used to calculate R1(Xa) and R1(Xa'), and their difference R2(Xa, Xa') can be calculated. In this case, Xa and Xa' are preferably 5 to 55 and 10 to 95, respectively, more preferably 5 to 45 and 15 to 95, and further preferably 5 to 40 and 20 to 95, respectively.
[0200] In another example, Xx, Xy and Xz (where Xx, Xy and Xz are the same or different values, where Xx≠Xy) can be used to calculate R4s(Xx, Xy, Xz), R4m(Xx, Xy, Xz), and then R5(Xd, Xe) (where Xd≠Xe) can be calculated. 1 , X 2 , X 3 ) Related X 1 ~X 3 In addition, Xd to Xe can be selected from the above R5 (X 1 , X 2 ) related to X 1 and X 2 Select from the range.
[0201] In another example, R1(Xa), R6(Xb) and R6(Xb') can be calculated using Xa, Xb and Xb' (here, Xa, Xb and Xb' are the same or different values, wherein Xb≠Xb'). In this case, Xa can be selected from the X range associated with the above R1(X), and Xb and Xb' can be selected from the X range associated with the above R6(X), respectively.
[0202] In another example, R1(Xa), R7(Xb), R7(Xb') and R8(Xb, Xb') can be calculated using Xa, Xb and Xb' (here, Xa, Xb and Xb' are the same or different values, wherein Xb≠Xb'). Xa is preferably 5 to 100, more preferably 5 to 95, and further preferably 55 to 95, Xb is preferably 10 to 95, more preferably 15 to 95, and further preferably 70 to 95, and Xb'≤Xb-5.
[0203] In the above example, R4s(Xx, Xy, Xz) and R4m(Xx, Xy, Xz) may be calculated instead of R1(Xa). Alternatively, R1(Xa) may be calculated instead of R4s(Xx, Xy, Xz) and R4m(Xx, Xy, Xz).
[0204] 4.2. Inference of factors that prolong the solidification time
[0205] The calculated index R can show different distributions depending on the type of various coagulation time prolonging factors (type of specimen) (refer to Figures 8 to 10 For example, as shown in the examples described below, R1(X) of lupus anticoagulant-positive (LA) tends to be greater than that of coagulation factor deficiency (Def) and coagulation factor inhibitor-positive (Inh). In addition, R2(X) of Inh with an inhibitor titer of 18 BU / mL or more is 1 , X 2 ) and R3(X 1 , X 2 ) has a tendency to be greater than Def (refer to Figures 11 to 14 ). In addition, for R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 ), R6(X), R7(X) and R8(X 1 , X 2 ) tends to be greater than Def in LA and low titer Inh, and R4(X 1 , X 2 , X 3 ) There is a positive relationship between Def and Inh and APTT (refer to Figures 15 to 17 ). Therefore, the index R can be used to infer the factor that prolongs the coagulation time of the test specimen.
[0206] In a preferred embodiment, the above R1(X), R2(X 1 , X 2 )、R3(X 1 , X 2 )、R4(X 1 , X 2 , X 3 )、R5(X 1 , X 2 )、R6(X)、R7(X)、R8(X 1 , X 2 ), or a combination of two or more of them to infer the coagulation time extension factor of the test specimen. More specifically, one or more X or one or more groups of X can be used. 1 and X 2 or X 1 ~X 3 Calculate one or more R1(X), one or more R2(X 1 , X 2 ), more than one R3(X 1 , X 2 ), more than one R4(X 1, X 2 , X 3 ), more than one R5(X 1 , X 2 ), one or more R6(X), one or more R7(X) or one or more R8(X 1 , X 2 ), or calculate them in combination, and infer the coagulation time extension factor of the test specimen based on any one of them, preferably any combination of two or more.
[0207] As the factors (types of specimens) for prolonging the coagulation time that can be inferred by the method of the present invention, lupus anticoagulant positive (LA), coagulation factor deficiency (Def) and coagulation factor inhibitor positive (Inh) can be cited. As an example of coagulation factor deficiency (Def), coagulation factor V (FV) deficiency, coagulation factor VIII (FVIII) deficiency, coagulation factor IX (FIX) deficiency, coagulation factor X (FX) deficiency, coagulation factor XI (FXI) deficiency, coagulation factor XII (FXII) deficiency can be cited, preferably FVIII deficiency. Preferably, the FVIII deficiency refers to a state in which the FVIII activity value is about 5% or less. As coagulation factor inhibitors, FVIII inhibitors, FV inhibitors, etc. can be cited. Preferably, the FVIII inhibitor positive refers to a state in which the inhibitor titer is more than 3BU / mL, preferably more than 5BU / mL. It should be noted that in this specification, the inhibitor titer is sometimes referred to as "titer", and the inhibitor titer in this specification is represented by Bethesda units (BU / mL).
[0208] In one example, the coagulation time extension factor of the test object is inferred based on R1(Xa). In another example, the coagulation time extension factor of the test object is inferred based on a combination of R1(Xa), R2(Xb, Xc) or R3(Xd, Xe) (where Xa, Xb, Xc, Xd and Xe are the same or different values, and Xb≠Xc, Xd≠Xe).
[0209] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R1(Xa), R2(Xb, Xc) and R3(Xd, Xe) (here, Xa, Xb, Xc, Xd and Xe are the same or different values to each other, where Xb≠Xc, Xd≠Xe).
[0210] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R1(Xa), R1(Xa') and R2(Xb, Xc) (here, Xa, Xa', Xb, Xc are the same or different values, where Xa≠Xa', Xb≠Xc).
[0211] In another example, the coagulation time prolonging factor of the specimen is estimated based on the combination of R1(Xa), R1(Xa'), and R2(Xa', Xa) (Xa≠Xa').
[0212] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R1(Xa), R1(Xa'), R2(Xb, Xc) and R3(Xd, Xe) (here, Xa, Xa', Xb, Xc, Xd and Xe are the same or different values to each other, and Xa≠Xa', Xb≠Xc, Xd≠Xe).
[0213] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R1(Xa), R1(Xa'), R2(Xa', Xa) and R3(Xd, Xe) (here, Xa, Xa', Xd and Xe are the same or different values to each other, where Xa≠Xa', Xd≠Xe).
[0214] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R4s (Xa, Xb, Xc), R4m (Xa, Xb, Xc) and R5 (Xd, Xe) (here, Xa~Xe are the same or different values, where Xa≠Xb, Xd≠Xe. Preferably, Xa=Xd, Xb=Xe).
[0215] In another example, the coagulation time extension factor of the specimen is estimated based on a combination of R1(Xa), R6(Xb) and R6(Xb') (where Xa, Xb and Xb' are the same or different values, and Xb≠Xb').
[0216] In another example, the coagulation time extension factor of the specimen is inferred based on the combination of R1(Xa), R7(Xb), R7(Xb') and R8(Xb, Xb') (here, Xa, Xb and Xb' are the same or different values, and Xb≠Xb').
[0217] Alternatively, in the method of the present invention, the above-mentioned indicator R (for example, any one of R1 to R8 or a combination thereof) can be combined with a known indicator for inferring the factor of prolonging the coagulation time, such as the percentage correction (PC) or Rossner index (RI) described later, or an indicator obtained by using T(X) instead of APTT in the calculation formula of PC and RI, etc., to infer the factor of prolonging the coagulation time of the test specimen.
[0218] In one embodiment, the coagulation time extension factor of the test specimen is inferred by comparing the index R calculated from the test specimen with the inference threshold value (hereinafter, also referred to as the threshold value) T. The threshold value T can be predetermined before implementing the method of the present invention. The threshold value T can be determined based on the index R calculated from a group of specimens whose coagulation time extension factors are known. The threshold value T can be set for each index used in the inference of the coagulation time extension factor; for example, threshold values T1 to T8 can be set for the above-mentioned R1 to R8, respectively. Alternatively, two or more threshold values T can be set for one index.
[0219] In one example, an index R of each sample is calculated from a sample group whose sample types are known (e.g., LA, Def, or Inh), and a threshold T is set based on their statistical values (e.g., mean ± [k × standard deviation], minimum value ÷ k, maximum value × k, etc., k ≥ 1). The sample type of the sample to be tested is inferred based on whether the index R of the sample to be tested exceeds the threshold T. An example of the inference step is described in detail below.
[0220] Step 1) There is a tendency that the R1(Xa) of LA is larger than other specimen types (Def and Inh). Therefore, by setting a threshold value T1 that can distinguish the R1(Xa) of LA from the R1(Xa) of Def and Inh, and comparing it with the R1(Xa) of the specimen to be tested, it is possible to infer whether the specimen type of the specimen to be tested is LA, Def, or Inh. Xa is preferably 5 to 100, more preferably 5 to 95, and further preferably 55 to 95. For example, if the R1(Xa) of the specimen to be tested is higher than the threshold value T1, it is inferred that the specimen to be tested is LA, and if the R1(Xa) of the specimen to be tested is lower than the threshold value T1, it is inferred that the specimen to be tested is Def or Inh. Preferred examples of the threshold value T1 at this time include the statistical value of R1(Xa) obtained from the specimen group of Def, the statistical value of R1(Xa) obtained from the specimen group of LA, and the like.
[0221] In step 2), the test sample estimated as Def or Inh based on R1(Xa) in step 1) can be further estimated as Def or Inh using other indicators.
[0222] In one example, the statistical value of R2(Xb, Xc) obtained from the sample group of Def can be used as the threshold value T2. Xb is preferably 5 to 55, more preferably 5 to 45, and further preferably 5 to 40, and Xc is preferably 10 to 95, more preferably 15 to 95, and further preferably 20 to 95, and Xb<Xc. If the R2(Xb, Xc) of the sample under test is higher than the threshold value T2, it can be inferred that the sample under test is Inh, and if the R2(Xb, Xc) of the sample under test is lower than the threshold value T2, it can be inferred that the sample under test is Def.
[0223] The above threshold value T2 can be further combined with other threshold values to make a more detailed inference on the type of the sample. For example, the Inh sample can be further classified according to the inhibitor titer.
[0224] Step 2A) Inh specimens with low inhibitor titers are difficult to distinguish from Def using threshold values T2. In this step, the statistical value of R3(Xd, Xe) obtained from the specimen group of Def is used as threshold T3, and is used in combination with the above-mentioned threshold value T2. Xd is preferably 5 to 90, more preferably 50 to 80, and Xe is preferably 10 to 95, more preferably 55 to 85, wherein Xe-Xd ≥ 5. Among the specimens inferred to be Def based on threshold T2 in step 2), specimens whose R3(Xd, Xe) is lower than threshold T3 can be further inferred to be Inh. The Inh specimen thus further inferred is Inh (Inh-L) with low inhibitor titer. This step can infer low-titer Inh with an inhibitor titer of less than 5, so it is clinically meaningful.
[0225] Step 2B) In this step, Inh is classified into stages according to the inhibitor titer. According to the statistical value of R3(Xd, Xe) obtained from the sample group of Def, two thresholds T3L and T3H (T3L<T3H) are set and used in combination with the above threshold T2. At this time, Xd is preferably 5 to 90, more preferably 50 to 80, and Xe is preferably 10 to 95, more preferably 55 to 85, wherein Xe-Xd≥5.
[0226] In this step, similarly to step 2A), among the specimens inferred to be Def based on threshold value T2 in step 2), the specimens whose R3 (Xd, Xe) is lower than threshold value T3L can be further inferred to be Inh. Such Inh specimens are Inh with low inhibitory titer (Inh-L). On the other hand, among the specimens inferred to be Inh based on threshold value T2 in step 2), the specimens whose R3 (Xd, Xe) is higher than threshold value T3H can be inferred to be Inh with high inhibitory titer (Inh-H). The remaining Inh with R3 (Xd, Xe) between threshold values T3L and T3H can be inferred to be Inh with intermediate inhibitory titer (Inh-M). Inh-H can be further inferred to be Inh with higher inhibitory titer (Inh-VH) using step 2C) described later.
[0227] Step 2C) can also classify Inh with higher inhibitory titer. In this step, the second threshold value T1' related to R1 (Xa) is set. As the threshold value T1', the statistical value obtained from the sample group of Def for R1 (Xa) used in the above step 1) and a value lower than the threshold value T1, or the statistical value obtained from the sample group of Def for R1 (Xa') etc. At this time, Xa>Xa', Xa is preferably 5-100, more preferably 5-95, further preferably 55-95, and Xa' is preferably 5-80, more preferably 5-50.
[0228] For example, when R1(Xa) is used in step 1), the threshold value T1' is set using R1(Xa'). Among the test specimens inferred to be Inh in step 2), the specimens whose R1(Xa') is higher than the threshold value T1' can be inferred to be Inh (Inh-VH) with a higher inhibitory titer (for example, a titer of 70 or more, preferably 80 or more, and more preferably 90 or more).
[0229] Step 3) R4s(Xx, Xy, Xz) (here, Xx is preferably 5-30, more preferably 5-25, further preferably 5-20, Xy is preferably 10-95, more preferably 25-95, further preferably 25-75, and Xz is preferably 5-95, or, Xx is preferably 45-70, more preferably 50-65, Xy is preferably 10-45, more preferably 10-35, and Xz is preferably 5-95, Xx≠Xy, preferably Xx<Xy) (hereinafter referred to as R4s for simplicity) is irregular according to APTT, but R4s of LA tends not to be a large value when APTT is prolonged. On the other hand, R4m (Xx, Xy, Xz) of LA (Xx, Xy, Xz are as described above) (hereinafter referred to as R4m for simplicity) tends to be larger than other specimen types (Def and Inh). Therefore, when the thresholds of R4s and R4m are set to T4s and T4m, and the R4s of the subject is lower than T4s and R4m is higher than T4m, the subject can be inferred to be LA. This step can be used to infer LA, preferably to distinguish LA from Def or Inh instead of the above step 1).
[0230] Step 3A) For the test specimens that are not inferred as LA in the above step 1) or step 3), two thresholds T5L and T5H (T5L<T5H) can be set for R5 (Xb, Xc) (Xb is preferably 5-35, more preferably 5-10, Xc is preferably 20-95, more preferably 35-65, preferably Xb<Xc) (hereinafter referred to as R5 for simplicity), and the test specimens with R5 higher than T5L and lower than T5H are inferred as Def, and the other cases are inferred as Inh. Furthermore, among the test specimens inferred as Inh, the specimens with R5 lower than the above T5L can be inferred as Inh (Inh-L) with low inhibitory titer. On the other hand, the remaining samples whose R5 is higher than T5H can be inferred to be Inh with higher inhibitory titer, among which the samples whose R4m is higher than the above-mentioned T4m can be inferred to be Inh with high inhibitory titer (Inh-H), and the lower samples can be inferred to be Inh with intermediate inhibitory titer (Inh-M).
[0231] Step 4) Alternatively, R6(Xb) is determined for the test specimen that was not inferred to be LA in the above step 1) or step 3). Here, Xb is preferably 35 to 95, more preferably 60 to 95, and further preferably 90 to 95. The statistical values of R6(Xb) obtained from the sample group of Def can be set as thresholds T6 and T6', respectively. If the R6(Xb) of the test specimen is lower than T6, the test specimen can be inferred to be Def, and if it is higher than T6, the test specimen can be inferred to be Inh. Then, if the R6(Xb) of the test specimen inferred to be Inh is higher than T6', the test specimen can be further inferred to be Inh (Inh-H) with a high inhibitory titer.
[0232] Step 5) Alternatively, for the test specimen that was not inferred to be LA in the above step 1) or step 3), R7(Xb), R7(Xb') and R8(Xb, Xb') are calculated. Here, Xb and Xb' are preferably 5 to 95, more preferably 70 to 95, wherein Xb≠Xb'. More preferably, Xb is preferably 10 to 95, more preferably 15 to 95, and further preferably 70 to 95, and Xb' is preferably 5 to 90, wherein Xb-5≥Xb'. The statistical values of R7(Xb), R7(Xb') and R8(Xb, Xb') obtained from the sample group of Def can be set as thresholds T7, T7' and T8, respectively. If R7(Xb) and R7(Xb') of the test specimen are lower than T7 and T7', respectively, the test specimen can be inferred to be Def. If R8(Xb, Xb') of the test object is higher than T8, the test object can be inferred to be Inh.
[0233] Step 6) LA can be distinguished from other cases by calculating R1(Xa) and R3(Xd, Xe). Xa is preferably 5-100, more preferably 5-95, and further preferably 55-95. Xd is preferably 5-90, more preferably 50-80, and Xe is preferably 10-95, more preferably 55-85, wherein Xe-Xd≥5. If the R1(Xa) of the sample under test is higher than the threshold value T1 and R3(Xd, Xe) is higher than the threshold value T3, the sample under test can be inferred to be LA. Preferred examples of the threshold values T1 and T3 at this time include the statistical values of R1(Xa) and R3(Xd, Xe) obtained from the sample group of Def, the statistical values of R1(Xa) and R3(Xd, Xe) obtained from the sample group of LA, and the like.
[0234] This step can be replaced by the above-mentioned step 1) or step 3) for the inference of LA, preferably the discrimination of LA from Def or Inh. Therefore, it can be understood that for the test specimens that are not inferred as LA in this step, the above-mentioned steps 2), steps 2A to C), step 3A), step 4) and step 5) can be continued.
[0235] In the above steps 1), 2), 2A to C), 3), 3A), 4), 5), and 6), as long as it is possible to distinguish different types of specimens and make inferences, "above threshold T1" can be used instead of "higher than threshold T1", or "below threshold T1" can be used instead of "lower than threshold T1", which is understandable to those skilled in the art. The same applies to thresholds T1', T2, T3, T3L, T3H, T4s, T4m, T5L, T5H, T6, T6', T7, T7', and T8.
[0236] In one embodiment, the percentage correction (PC) or Rosner Index (RI) can be used instead of the above step 1 using R1(X) or step 3 using R4s and R4m to infer that the sample type of the sample under test is LA, Def or Inh. PC and RI can be calculated by the following formula.
[0237] Percent correction (PC) (%) = [(S-M) / (S-N)] × 100
[0238] Rossner Index (RI) (%) = [(M-N) / S] × 100
[0239] (N: APTT of sample N, M: APTT of sample M, S: APTT of sample S)
[0240] PC is less than Def and Inh for LA, and RI is greater than Def and Inh for LA (refer to Figures 18 to 20 ). It is preferred to calculate the statistical value for PC or RI from the sample group of LA or Def as the threshold of PC or RI. If the PC of the sample under test is below the threshold (or lower than), the sample under test can be inferred to be LA. Alternatively, if the RI of the sample under test is above the threshold (or higher than), the sample under test can be inferred to be LA. Alternatively, in the above-mentioned formula of PC or RI, arbitrary Ts(X), Tm(X), Tn(X) can be used instead of APTT of samples S, M, N respectively to make the same inference.
[0241] The inference result of the extended factor (specimen type) of the specimen to be tested can be output in any form. The coagulation time, coagulation reaction curve, coagulation reaction end point, T(X) curve and other information of the specimen to be tested can be output together with the inference result of the specimen type of the specimen to be tested as needed. The same information can also be output for the mixed specimen. It is preferred to output the inference result of the specimen type of the specimen to be tested and the coagulation time together.
[0242] 5. Inference Process
[0243] As an embodiment, an exemplary process of inferring the factor of prolonging the coagulation time of a test specimen using the method of the present invention is shown in Fig.21 The following shows Fig.21 The detailed steps of the process.
[0244] s1: Measure the coagulation reaction of the specimen.
[0245] s2: Obtain the response curve Ps(i) of the specimen under test.
[0246] s3: When the coagulation time measured by Ps(i) is prolonged, Ts(X) of the specimen is calculated.
[0247] s4: Measure the coagulation reaction of the mixed sample.
[0248] s5: Obtain the reaction curve Pm(i) of the mixed sample.
[0249] s6: Calculate Tm(X) of the mixed sample from Pm(i).
[0250] s7: Calculate the index Rj from Ts(X), Tm(X), and Tn(X).
[0251] (The index Rj is preferably at least one selected from the above R1 to R8)
[0252] s8: Compare the indicator Rj with the threshold Tj.
[0253] s9: Infer the extension factor of the specimen under test based on the comparison result.
[0254] s10: Output clotting time and extension factor.
[0255] One embodiment of the method for estimating a coagulation time extension factor of the present invention according to the above-mentioned estimating process comprises the following steps:
[0256] 1-i) a step of obtaining a response curve Ps(i) of the test specimen;
[0257] 1-ii) when the coagulation time of the sample is prolonged, a step of obtaining a coagulation reaction curve Pm(i) of a mixed sample of the sample and a normal sample and a coagulation reaction curve Pn(i) of the normal sample;
[0258] 1-iii) a step of obtaining Ts(X) from Ps(i), obtaining Tm(X) from Pm(i), and obtaining Tn(X) from Pn(i);
[0259] 2-i) Process of calculating one or more indexes Rj
[0260] (Here, j ≥ 1,
[0261] The index Rj is calculated based on at least one selected from Ts(X), Tm(X) and Tn(X).
[0262] At least one of the indicators Rj is calculated based on at least Tm(X);
[0263] 2-ii) a step of comparing the index Rj with a threshold value Tj;
[0264] 2-iii) A step of estimating a factor that prolongs the coagulation time of the test sample based on the comparison result.
[0265] Preferably, the factor prolonging the clotting time is lupus anticoagulant positivity, coagulation factor deficiency, or coagulation factor inhibitor positivity.
[0266] 6. Inference of factors that prolong coagulation time based on machine learning models
[0267] In another embodiment of the method of the present invention, the coagulation time prolonging factor of the sample to be tested can be inferred based on the inference model of the coagulation time prolonging factor (machine learning model) constructed by machine learning. The mentor data used for machine learning uses data related to Tm(X) obtained from the mentor specimen group, and data on the type of coagulation time prolonging factor (specimen type). For example, a machine learning model for inferring the coagulation time prolonging factor of the sample to be tested is constructed by machine learning using a feature quantity representing the characteristics of Tm(X) for each specimen of the mentor specimen group, such as the above-mentioned index R, as an explanatory variable and using the data on the specimen type for each specimen of the mentor specimen group as a target variable.
[0268] The mentor sample group can use a blood sample group with known sample types. In a preferred embodiment, the mentor sample group includes LA, Def and Inh as sample types showing prolonged coagulation time. The sample type Def can be preferably divided into two types, Def-1 with low activity and other Def-2, according to the relative high and low activity of the factor. In addition, the sample type Inh can be preferably divided into three types, Inh-H with high titer, Inh-L with low titer, and Inh-M with medium titer, according to the relative high and low titer of the inhibitor, or can be divided into two types, Inh-H with high titer and Inh-LM with medium and low titer. As the characteristic quantity used in the explanatory variable, Ts(X)-Tn(X), Tm(X)-Tn(X), the above-mentioned index R, such as the above-mentioned R1 to R8 (preferably the above-mentioned R1(Xa), R1(Xa'), R2(Xb, Xc) and R3(Xd, Xe)). Any one of these indices may be used, or any two or more, or any three or more may be used in combination. The index R may be further combined with conventionally known indices such as the above-mentioned PC and RI to be used as a feature amount.
[0269] As machine learning algorithms for constructing machine learning models, well-known machine learning algorithms such as support vector machine (SVM), neural network (NN), decision tree, random forest, and k-nearest neighbor algorithm can be cited. The verification data is input into the constructed model to calculate the inference result of the coagulation time extension factor. The model in which the inference result best matches the actual result, for example, the model in which the accuracy of the inference result relative to the actual result is the largest, or the model in which the error between the inference result and the actual result is the smallest can be selected as the best model.
[0270] The constructed machine learning model outputs an inference result (LA, Def, or Inh) of the coagulation time prolonging factor of the sample based on a feature value (ie, data corresponding to the above-mentioned explanatory variable) representing the characteristics of Tm(X) of the sample.
[0271] 7. Application in other coagulation reaction measurement methods
[0272] In the above, the method for inferring the factor of prolonging the coagulation time of the present invention is described by taking the case of measuring the coagulation reaction based on the amount of scattered light as an example. However, for those skilled in the art, the above-mentioned method based on the amount of scattered light can be used in a method using other coagulation reaction measuring methods (e.g., coagulation reaction measuring methods based on transmittance, absorbance, viscosity, etc.), and therefore, such application is included in the scope of the present invention.
[0273] 8. Procedures and devices
[0274] The above-mentioned method for estimating the factor for prolonging the coagulation time of the present invention can be automatically performed using a computer program. Therefore, one embodiment of the present invention is a program for performing the above-mentioned method for estimating the factor for prolonging the coagulation time of the present invention. In a preferred embodiment, the program of the present invention is used to implement the above-mentioned Fig.21 In addition, the series of steps of the method of the present invention described above can be automatically performed using an automatic analyzer. Therefore, one embodiment of the present invention is a device for performing the method of estimating the factor of prolonging the coagulation time of the present invention described above.
[0275] Hereinafter, one embodiment of the device of the present invention will be described. One embodiment of the device of the present invention is as follows Fig. 22 The automatic analyzer 1 is shown. The automatic analyzer 1 includes a control unit 10 , an operation unit 20 , a measurement unit 30 , and an output unit 40 .
[0276] The control unit 10 controls the overall operation of the automatic analyzer 1. The control unit 10 can be composed of a computer (personal computer, etc.), for example. The control unit 10 has a CPU, a memory, a storage, a communication interface (I / F), etc., and performs processing of instructions from the operation unit 20, control of the operation of the measuring unit 30, storage or data analysis of the measurement data received from the measuring unit 30, storage of the analysis results, and control of outputting the measurement data or the analysis results using the output unit 40. In addition, the control unit 10 can be connected to other devices such as external media and a host computer. In addition, in the control unit 10, the computer that controls the operation of the measuring unit 30 and the computer that analyzes the measurement data can be the same or different.
[0277] The operation unit 20 obtains input from the operator and transmits the obtained input information to the control unit 10. For example, the operation unit 20 has a user interface (UI) such as a keyboard and a touch panel. The output unit 40 outputs the measurement data of the measurement unit 30, the coagulation reaction curve P based on the data, the coagulation reaction end point E, the coagulation time, T(X), the index R, the inference result of the coagulation time extension factor of the specimen (for example, LA, Def, Inh, or other information) and other analysis results under the control of the control unit 10. For example, the output unit 40 has a display device such as a display.
[0278] The measuring unit 30 performs a series of operations for the coagulation test and obtains the measurement data of the coagulation reaction of the sample containing the blood specimen. The measuring unit 30 includes: various instruments and analysis modules required for the coagulation test, such as a sample container for storing the blood specimen, a reagent container for storing the test reagent, a reaction container for the reaction between the specimen and the reagent, a detector for dispensing the specimen, diluent, reagent, etc. into the reaction container, a light source, a detector for detecting scattered light or transmitted light from the sample in the reaction container, a data processing circuit for sending data from the detector to the control unit 10, and a control circuit for receiving instructions from the control unit 10 to control the operation of the measuring unit 30.
[0279] The control unit 10 infers the coagulation time extension factor of the specimen based on the data measured by the measuring unit 30. This analysis may include the acquisition of the above-mentioned coagulation reaction curve P and coagulation time, the acquisition of the coagulation reaction end point E and T(X), the calculation of the index R, etc. In addition, the control unit 10 can use the calculated index R to infer the coagulation time extension factor of the specimen. Alternatively, the coagulation reaction curves P and E can be obtained by the control unit 10 based on the measurement data from the measuring unit 30, or can be obtained by other devices such as the measuring unit 30 and sent to the control unit 10. The control unit 10 can store various parameters (such as calculation formulas for calculating X and R) for calculating the coagulation time, E, T(X), and R of the specimen. In addition, the control unit 10 can store parameters (such as the above-mentioned threshold T, etc.), machine learning models, etc. for inferring the coagulation time extension factor of the specimen. Alternatively, the control unit 10 can also introduce the parameters and reference values stored in an external device or network during analysis.
[0280] The above analysis can be performed by a program for executing the method of the present invention. Therefore, the control unit 10 may be equipped with a program for executing the method of estimating the coagulation time prolonging factor of the present invention.
[0281] The analysis result in the control unit 10 is sent to the output unit 40 and output. The output may be in any form such as display on a screen, sending to a host computer, printing, etc. The output information from the output unit may include data of a coagulation reaction curve, a coagulation reaction end point E, coagulation time, T(X), an index R, and an inference result of a coagulation time extension factor of a specimen. The type of output information from the output unit may be controlled by the program of the present invention.
[0282] Example
[0283] Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
[0284] method
[0285] 1) Specimen
[0286] · Normal specimen (NP) was mixed with normal plasma (N=1) using CRYOcheck from Precision BioLogic (total N=1).
[0287] LA-positive specimens (LA) used lupus anticoagulant-positive plasma from George King Bio-Medical, Inc. (N=1 in each of 6 batches) and plasma obtained by diluting one of the batches 10-fold with normal plasma (N=1) (total N=7; L-1 to L-7).
[0288] ·FVIII-deficient plasma (Def) used coagulation factor VIII-deficient plasma (N=1 in each of four batches) from George King Bio-Medical, Inc. with a confirmed FVIII activity value of less than 1% and a total of four types of plasma (N=1 in each batch) obtained by adding 1% and 5% normal plasma to two of the batches, respectively (total N=8; D-1 to D-8).
[0289] ·FVIII inhibitor-positive specimens (Inh) used specimens in which inhibitors were added to factor VIII-deficient plasma from George King Bio-Medical, Inc. (N=1 in each of the three batches) and a total of seven types of plasma (N=1 in each batch) obtained by diluting the three batches with normal plasma to 2 to 24 times (total N=10; I-1 to I-10). The inhibitor titer of the specimen (unit is BU / mL, hereinafter also referred to as titer) is determined according to the product instructions. The titer of the specimen after dilution with normal plasma is calculated based on the titer before dilution and the dilution rate.
[0290] A normal sample (NP) was used to prepare a mixed sample of each sample.
[0291] 2) Coagulation reaction measurement
[0292] For the assay reagents, APTT assay reagent Coagpia APTT-N APTT reagent (manufactured by Sekisui Medical Co., Ltd.) was used as the first reagent, and Coagpia APTT-N calcium chloride solution (25 mM calcium chloride solution, manufactured by Sekisui Medical Co., Ltd.) was used as the second reagent. The coagulation reaction of the sample containing the specimen was measured using a coagulation automatic analyzer CP3000 (manufactured by Sekisui Medical Co., Ltd.). After 50 μL of the specimen was heated at 37°C in a cuvette for 45 seconds, 50 μL of the first reagent at about 37°C was added, and after further 171 seconds, 50 μL of the second reagent was added to induce the coagulation reaction. The reaction was carried out at 37°C. The coagulation reaction was measured by irradiating the cuvette with light of a wavelength of 660 nm using an LED as a light source to measure the amount of scattered light of the 90-degree side scattered light at intervals of 0.1 seconds. The measurement time was 360 seconds. When the sample was measured while being heated, the sample was heated at 37° C. for 12 minutes using the sample heating function of the analyzer before the addition of the measurement reagent.
[0293] 3) Obtaining the coagulation reaction curve
[0294] After smoothing processing including noise removal is performed on the photometric data from each sample, a zero adjustment process is performed so that the amount of scattered light at the start of photometry is 0, thereby creating a coagulation reaction curve P(i).
[0295] 4) Detection of the end point E of the coagulation reaction and determination of APTT
[0296] The earliest time when the cumulative ratio Z(i) of the coagulation reaction curve P(i) (see PCT / JP2020 / 048676) is less than the cumulative ratio threshold Zs is taken as the coagulation reaction end point E. The cumulative ratio threshold Zs is 1.001. The time T(50) when P(i) reaches 50% of E is calculated and determined as APTT. The cumulative ratio Z(i) at time i is calculated as follows:
[0297] Cumulative ratio Z(i) = Pb(i) / Pa(i)
[0298] Pa(i) = the sum from P(i-20) to P(i-1)
[0299] Pb(i) = the sum from P(i+1) to P(i+20)
[0300] 5) Calculation of T(X)
[0301] For each sample, the time T(X) when P(i) reaches X% of E detected in 3) is calculated according to the following formula. X is set to 100 at intervals of 1 from 1 to 100, and T(1) to T(100) are calculated. It should be noted that T(50) when X=50 corresponds to APTT.
[0302] P(T(X))=E×X%
[0303] Coagulation reaction of the specimen
[0304] Figure 3 P(i) (vertical axis: scattered light amount) (upper graph) and T(X) (lower graph) of each test specimen of LA, Def, and Inh are shown. Figure 3 A shows the data of LA, Figure 3 B shows the data of Def, Figure 3 The data of Inh are shown in C. The data of normal samples (NP) are also shown in each figure (dashed line).
[0305] Figure 4 P(i) (vertical axis: scattered light amount) (upper graph) and T(X) (lower graph) of mixed samples (mixing ratio; sample:NP=1:1) prepared from the respective samples of LA, Def, and Inh are shown. Figure 4 A shows the data of LA, Figure 4 B shows the data of Def, Figure 4 The data of Inh are shown in C. The data of normal samples (NP) are also shown in each figure (dashed line).
[0306] Table 1 shows the inhibitory titer and APTT of the test specimens (LA, Def, Inh), as well as the APTT (APTT before heating, a) of the mixed specimens prepared from each test specimen (mixing ratio; test specimen: NP = 1:1), the APTT of the specimen after heating the mixed specimen (37°C, 12 minutes) (APTT after heating, b), and the APTT difference of the mixed specimen before and after heating (b-a).
[0307] [Table 1]
[0308]
[0309] Figure 5 APTT of the test sample is shown in A. The APTT distribution ranges of LA, Def, and Inh overlapped, and it was confirmed that the type of the sample could not be distinguished by APTT.
[0310] The distribution of each sample type is shown in the table below for the APTT difference (b-a) of the mixed sample before and after heating. Figure 5 B, Inh samples were plotted against titers. Figure 5C. Although there are samples in Inh that produce APTT difference (b-a) by heating the mixed sample, APTT hardly changes in LA and Def by heating the mixed sample. Although the APTT difference (b-a) of Inh increases in accordance with the titer, it is not a linear relationship. Inh with a titer of 5 or less cannot be distinguished from Def by APTT difference (b-a).
[0311] Example 1
[0312] Figure 6 A shows the P(i) of three samples with the same APTT (around 100 seconds) for different sample types together with the data of NP. The shape of P(i) varies for each sample type even when the APTT is the same. The shapes of P(i) of Def and Inh have similar trends, and the rise of either curve is relatively slow. In LA, even when the APTT is prolonged, the rise of the curve is relatively steep.
[0313] On the other hand, the coagulation reaction of the mixed sample shows a behavior different from that of the sample being tested. Figure 6 B shows that Figure 6 P(i) of the mixed samples (mixing ratio; sample:NP=1:1) prepared from the three samples shown in A. In the mixed samples derived from Def and Inh (Def-M11 and Inh-M11), the shape of P(i) was close to NP, and the APTT was within the normal range (24 to 39 seconds). On the other hand, in the mixed sample derived from LA (LA-M11), the shape of P(i) was similar to that of the original sample ( Figure 6 Similar to LA of A, although APTT was also shortened, it was still prolonged.
[0314] Figure 7 A to C show Figure 6 A and B are graphs of T(X) (Ts(X) and Tm(X)) of the test specimen and the mixed specimen. Figure 7 A shows the data of LA and its mixed sample LA-M11, Figure 7 B shows the data of Def and its mixed sample Def-M11, Figure 7 C shows the data of Inh and its mixed sample Inh-M11. Each figure also shows Tn(X) for NP. Mainly because Tm(X) is shifted downward (closer to Tn(X)) compared with Ts(X), the relative arrangement of the curves representing Ts(X), Tm(X), and Tn(X) varies depending on the type of sample. The downward shift of Tm(X) is in LA( Figure 7 A) is less, and in Def and Inh( Figure 7B and C). The results suggest that the difference between Ts(X) and Tm(X) [Ts(X)-Tm(X)] and the difference between Tm(X) and Tn(X) [Tm(X)-Tn(X)] at any X are different depending on the type of specimen. That is, [Ts(X)-Tm(X)] of Def and Inh is larger than that of LA, while [Tm(X)-Tn(X)] of Def and Inh is smaller than that of LA. In addition, the difference between [Ts(X)-Tm(X)] or [Tm(X)-Tn(X)] between Def and Inh is small.
[0315] Example 2
[0316] for Figure 6 The test specimens (LA, Def and Inh) shown in A were mixed specimens with a mixing ratio (test specimen: NP) of 1:9, 1:1, and 9:1. Tm(X) of each mixed specimen was calculated. The same values as in Example 1 were used for Ts(X) and Tn(X). Using these Tm(X), Ts(X) and Tn(X), the following indices were calculated for each mixed specimen.
[0317] FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100 Figure 8 A~C are marked with Figure 6 FT1(X) calculated from the mixed sample derived from each sample shown in A. Figure 8 A shows the data of a mixed sample (1:9 mixed sample) with a mixing ratio (test sample: NP) of 1:9. Figure 8 B shows the data of a mixed sample (1:1 mixed sample) with a mixing ratio (test sample: NP) of 1:1. Figure 8 C shows data of a mixed sample (9:1 mixed sample) having a mixing ratio (test sample: NP) of 9: 1. In each figure, the single-dot chain line represents the LA-derived sample, the double-dot chain line represents the Def-derived sample, and the solid line represents the Inh-derived sample. Figure 8 In A to C, LA's FT1(X) is greater than Def and Inh, and X changes little in the range of 0 to 60, close to a horizontal state. On the other hand, Def and Inh's FT1(X) decrease as X increases, and are minimum near X = 95. Inh's FT1(X) is slightly greater than Def, and the difference in FT1(X) between the two tends to increase as X decreases. These results suggest that LA can be distinguished from Def and Inh based on FT1(X), and there is a possibility that Def and Inh can be distinguished from each other.
[0318] like Figure 8 As shown, FT1(X) of Def and Inh is minimum near X=95, so the following indexes are calculated for each mixed sample.
[0319] ΔFT1 X-95 =[FT1(X)-FT1(95)]
[0320] Will target Figure 8 ΔFT1 of mixed samples A to C X-95 The plots are shown in Fig. 9 A to C. Especially when X is 40 or less, ΔFT1 in Def and Inh X-95 If the ratio of the sample to be tested in the mixed sample is higher, the ΔFT1 between Def and Inh will be X-95 The difference is even greater. Based on the results, it is suggested that the X-95 To distinguish Def and Inh.
[0321] Example 3
[0322] For a total of three samples, one sample of Def (APTT of 108 seconds) and two samples of Inh with different titers (titer 18 and titer 5, APTT of 105 seconds and 57 seconds, respectively), a mixed sample with a mixing ratio (test sample: NP) of 1:1 was prepared. Tm(X) of each mixed sample was calculated. Tn(X) used the same value as in Example 1. Using these Tm(X) and Tn(X), the following indexes were calculated for each mixed sample.
[0323] FT2(X)=Tm(X) / Tn(X)×100
[0324] FT3(X,95)=(Tm(X)-Tm(95)) / (Tn(X)-Tn(95))×100
[0325] Fig.10 A to C show ΔFT1 of three samples X-95 ( Fig.10 A), FT2(X)( Fig.10 B) and FT3(X,95)( Fig.10 In each figure, the double-dashed line represents the mixed sample derived from Def, and the solid line and the long dashed line represent the mixed sample derived from Inh with a titer of 18 and a titer of 5, respectively.
[0326] ΔFT1 X-95In the results, although the Inh with a titer of 5 is between Def and Inh with a titer of 18, it is difficult to distinguish from Def. Although FT2(X) has a difference in value between Def and Inh, as X becomes smaller, the values of Def and Inh with a titer of 18 are close. FT3(X, 95) has a difference in value between Def and Inh, and as X becomes smaller (especially in the range of X about 40 or less), the values of Def and Inh with a titer of 18 become larger. Based on these results, it is suggested that FT3(X) is suitable as an index for more detailed discrimination between Def and Inh.
[0327] Example 4
[0328] Using the indicators FT1(X), ΔFT1 X-95 The LA, Def, and Inh were identified by using FT3(X, 95). A mixed sample with a mixing ratio (sample to be tested: NP) of 1:1 was used for the calculation of Tm(X).
[0329] 1) FT1(X), ΔFT1
[0330] The following indices 1 to 3 are calculated for the test specimen (LA, Def, Inh).
[0331] Indicator 1: FT1 (95)
[0332] Indicator 2: FT1(10)
[0333] Indicator 3: ΔFT1 10-95 =[FT1(10)-FT1(95)]
[0334] [FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100]
[0335] For indicators 1 to 3, the average value and standard deviation (SD) of Def (D-1 to D-8) are respectively calculated, and the average value + 4SD is set as the threshold value of each indicator.
[0336] The calculated indices 1 and 2 for each sample are shown in Fig.11 A and B, the index 3 of Def and Inh is shown in Fig.11 C. In addition, the graph of the index 3 of Inh against the potency is plotted in Fig.11 D. The dashed line in each graph indicates the threshold value.
[0337] Index 1 shows that LA is higher than Def and Inh ( Fig.11 A). Inh's indicators 2 and 3 tend to be higher than Def, and some Inh cannot be distinguished from Def ( Fig.11B, C). Inh with a titer of 5 or less, the index 3 is below the threshold and cannot be distinguished from Def. However, in Inh with a titer of more than 5, the index 3 increases with the titer and exceeds the threshold, showing a distribution different from Def ( Fig.11 D).
[0338] The indicators 1 to 3 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the following criteria.
[0339] <Estimation criteria>
[0340] (i) Indicator 1 > threshold: "LA"
[0341] The remaining samples were further classified in the following order.
[0342] (ii) When indicator 2 is less than the threshold and indicator 3 is less than the threshold: "Def"
[0343] (iii) When index 2 is less than the threshold and index 3 is greater than or equal to the threshold: “Inh(In2)”
[0344] (iv) When indicator 2 ≥ threshold and indicator 3 ≥ threshold: “Inh(In1)”
[0345] Table 2 shows the indicators 1 to 3 of each sample, the comparison results of these indicators with the threshold value, and the inferred sample type. LA can be distinguished from other sample types (Def and Inh) based on this inference standard, and Inh with a titer greater than 5 (In2; I-4 to I-7, I-10) can be accurately distinguished. In addition, high-titer Inh with a titer of 92 or more (In1; I-8 to I-9) can be distinguished by indicator 2. On the other hand, low-titer Inh with a titer of 5 or less (I-1 to I-3) can be distinguished from Def.
[0346] [Table 2]
[0347]
[0348] 2) FT1(X), ΔFT1, FT3(X 1 , X 2 )
[0349] The following indices 1 to 3 are calculated for the test specimen (LA, Def, Inh).
[0350] Indicator 1: FT1 (95)
[0351] Indicator 2: ΔFT1 10-95 =[FT1(10)-FT1(95)]
[0352] Indicator 3: FT3 (10, 95)
[0353] [FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100
[0354] FT3(X 1 , X 2 )=(Tm(X 1 )-Tm(X 2 )) / (Tn(X 1 )-Tn(X 2 ))
[0355] ×100〕
[0356] For indicators 1 and 2, the average value of Def (D-1 to D-8) + 4SD is set as the threshold value. For indicator 3, the average value of Def (D-1 to D-8) - 2SD is set as the threshold value.
[0357] The index 3 of Def and Inh is shown in Fig.12 A, Inh index 3 is plotted against potency. Fig.12 B. The dotted line in each figure indicates the threshold value. The index 3 of Def does not vary much among the specimens. Inh is divided into specimens with index 3 lower than Def, specimens higher than Def, and specimens with the same degree as Def ( Fig.12 A). The index 3 of Inh is proportional to the titer and is less than the threshold value in the three specimens with a titer of less than 5 ( Fig.12 B).
[0358] The indicators 1 to 3 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the following criteria.
[0359] <Estimation criteria>
[0360] (i) Indicator 1 > threshold: "LA"
[0361] The remaining samples were further classified in the following order.
[0362] (ii) When indicator 2 is less than the threshold and indicator 3 is greater than or equal to the threshold: "Def"
[0363] (iii) In the case where indicator 2 ≥ threshold and indicator 3 ≥ threshold: “Inh(In1)”
[0364] (iv) When index 2 is less than the threshold and index 3 is less than the threshold: "Inh(In2)"
[0365] Indicators 1 to 3 of each sample, the comparison results of these indicators and the threshold value, and the estimated sample type are shown in Table 3. According to this estimation standard, LA, Def, and Inh can be distinguished from each other, and low-titer Inh (In2; I-1 to I-3) with a titer of 5 or less and other Inh samples (In1; I-4 to I-10) can be distinguished.
[0366] [Table 3]
[0367]
[0368] 3) FT1(X), ΔFT1, FT3(X 1 , X 2 )
[0369] Indicators 1 to 3 calculated in 2) above are used. For the thresholds, the same thresholds as in 2) above are used for indicators 1 to 2, and two thresholds, threshold L: average value of Def (D-1 to D-8) - 2SD and threshold H: average value of Def (D-1 to D-8) + 4SD, are used for indicator 3. Indicators 1 to 3 are compared with the thresholds, and based on the comparison results, the sample type of the sample to be tested is inferred according to the following criteria.
[0370] <Estimation criteria>
[0371] (i) Indicator 1 > threshold: "LA"
[0372] The remaining samples were further classified in the following order.
[0373] (ii) When index 2 is less than the threshold value and index 3 is greater than or equal to the threshold value L: "Def"
[0374] (iii) When index 3 > threshold H: "Inh(In1)"
[0375] (iv) When index 3 ≥ threshold L and index 3 ≤ threshold H: “Inh(In2)”
[0376] (v) When index 3 < threshold value L: "Inh(In3)"
[0377] Indicators 1 to 3 of each sample, the comparison results of these indicators with the threshold value, and the inferred sample type are shown in Table 4. According to this inference standard, LA, Def, and Inh can be distinguished from each other, and Inh can be classified into three stages corresponding to the titer: low titer (≤5) (In3), medium titer (In2), and high titer (≥26) (In1).
[0378] [Table 4]
[0379]
[0380] 4) 9:1 mixed specimen
[0381] The following indices 1 and 2 were calculated for the test sample (LA, Def, Inh). A mixed sample having a mixing ratio (test sample: NP) of 9:1 was used for the calculation of Tm(X).
[0382] Indicator 1: FT1(10)
[0383] Indicator 2: FT3 (10, 85)
[0384] [FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100
[0385] FT3(X 1 , X 2 )=(Tm(X 1 )-Tm(X 2 )) / (Tn(X 1 )-Tn(X 2 ))
[0386] ×100〕
[0387] For indicator 1, the average value of Def (D-1 to D-8) + 4SD is set as the threshold value. For indicator 2, two threshold values are set: threshold L: average value of Def (D-1 to D-8) - 2.5SD and threshold H: average value of Def (D-1 to D-8) + 2.5SD.
[0388] The calculated indices 1 to 2 for each sample are shown in Fig.13 A to B, the graphs showing the Inh index 2 plotted against the titer are shown in Fig.13 C. Fig.13 The dashed line in A represents the threshold of indicator 1. Fig.13 The dotted line in B and C indicates the threshold value L of the index 2, and the long dashed line indicates the threshold value H of the index 2. The index 1 of LA shows a higher value than Def and Inh ( Fig.13 A). The index 2 of LA and Inh tends to be higher than that of Def. Some of the index 2 of Inh cannot be distinguished from that of Def ( Fig.13 B) Although the index 2 of Inh increases in proportion to the titer, it does not exceed the threshold L or threshold H at low titers and cannot be distinguished from Def ( Fig.13 C).
[0389] The indexes 1 and 2 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the following criteria.
[0390] <Estimation criteria>
[0391] (i) Indicator 1 > threshold: "LA"
[0392] The remaining samples were further classified in the following order.
[0393] (ii) When index 2 ≥ threshold L and index 2 ≤ threshold H: "Def"
[0394] (iii) When index 2 > threshold H: "Inh(In1)"
[0395] (iv) When indicator 2 is less than threshold value L: “Inh(In2)”
[0396] Indicators 1 and 2 of each sample, the comparison results of these indices and threshold values, and the estimated sample types are shown in Table 5. According to this estimation standard, LA, Def, and Inh can be distinguished from each other, and low titer (≤5) Inh (In2; I-1 to I-3) can be distinguished.
[0397] Under this inference standard, when there is Inh with index 2 being threshold L to threshold H, there is a possibility that it cannot be distinguished from Def. However, it is advantageous over conventional methods in that it is possible to distinguish LA and some Inh without incubating the specimen for a long time as in the delayed reaction of the cross-mixing test.
[0398] [Table 5]
[0399]
[0400] 5) 1:9 mixed specimen
[0401] The following indices 1 to 4 were calculated for the test sample (LA, Def, Inh). A mixed sample having a mixing ratio (test sample: NP) of 1:9 was used for the calculation of Tm(X).
[0402] Indicator 1: FT1 (95)
[0403] Indicator 2: FT1(10)
[0404] Indicator 3: ΔFT1 10-95 =[FT1(10)-FT1(95)]
[0405] Indicator 4: FT3 (10, 95)
[0406] [FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100
[0407] FT3(X 1 , X 2)=(Tm(X 1 )-Tm(X 2 )) / (Tn(X 1 )-Tn(X 2 ))
[0408] ×100〕
[0409] For indicators 1 and 4, the average value of Def (D-1 to D-8) + 3SD is set as the threshold value. For indicators 2 and 3, the average value of Def (D-1 to D-8) + 2SD is set as the threshold value.
[0410] The calculated indices 1 to 4 for each sample or Def and Inh are shown in Fig.14 A to D, the Inh index 4 is plotted against the potency. Fig.14 E. The dashed line in each graph indicates the threshold value.
[0411] Although indicators 1, 2, and 4 have a tendency that LA is higher than Def and Inh, it is impossible to distinguish Def from Inh ( Fig.14 A, B, D). Inh's index 3 tends to be higher than Def. Some Inh cannot be distinguished from Def ( Fig.14 C) Inh index 4 has a tendency to increase in proportion to the titer ( Fig.14 E).
[0412] The indicators 1 to 4 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the following criteria.
[0413] <Estimation criteria>
[0414] (i) Indicator 1 > threshold and indicator 4 > threshold: "LA"
[0415] The remaining samples were further classified in the following order.
[0416] (ii) Index 2 < threshold, Index 3 < threshold: "Def"
[0417] (iii) When index 3 is less than the threshold and index 4 is less than or equal to the threshold: "Inh(In3)"
[0418] (iv) When indicator 3 ≥ threshold and indicator 4 ≤ threshold: “Inh(In2)”
[0419] (v) When index 3 ≥ threshold and index 4 > threshold: "Inh(In1)"
[0420] Indicators 1 to 4 of each test specimen, the comparison results of these indicators with the threshold value, and the inferred specimen type are shown in Table 6. According to this inference standard, LA, Def, and Inh can be accurately distinguished except for one specimen (I-3) of Inh. In addition, this standard can use mixed specimens with a low ratio of test specimens, so the specimen type can be inferred using a small amount of test specimens. This can bring the advantage of being able to reduce the amount of blood collected from the subject. For example, when a prolonged coagulation time is found in the test specimen, there is no need to collect blood from the subject again, and the remaining specimens can be used to infer the specimen type.
[0421] [Table 6]
[0422]
[0423] Example 5
[0424] 1) 1:1 mixed specimen
[0425] The following indices 1 to 3 are calculated for the test sample (LA, Def, Inh). A mixed sample having a mixing ratio (test sample: NP) of 1:1 is used for the calculation of Tm(X).
[0426] Index 1 = FT4s (5, 35, 50)
[0427] Index 2 = FT4m (5, 35, 50)
[0428] Index 3 = FT5 (5, 35)
[0429] 〔FT4s(X 1 , X 2 , X 3 )=[(Ts(X 2 )-Ts(X 1 )) / Ts(X 3 )]×100
[0430] FT4m(X 1 , X 2 , X 3 )=[(Tm(X 2 )-Tm(X 1 )] / Tm(X 3 )]×100
[0431] FT5(X 1 , X 2 )=[(Tm(X 2 )-Tm(X 1 ))×100〕
[0432] The average value and standard deviation (SD) of Def (D-1 to D-8) are calculated for indicators 1 to 3, respectively. For the threshold value, the average value + 2SD is used for indicator 1, the average value - 2SD is used for indicator 2, and the threshold value L, which is the average value - 1.5SD, and the threshold value H, which is the average value + 2SD, is used for indicator 3. The calculated indicators 1 to 3 for each test sample are shown in Fig.15 A, B and C, and also plotting the index 3 of Inh against the potency in Fig.15 D. The dashed and long dashed lines in each graph indicate the threshold value.
[0433] The indicators 1 to 3 are compared with the threshold value, and based on the comparison result, the sample type of the sample to be tested is estimated according to the following criteria.
[0434] <Estimation criteria>
[0435] (i) When indicator 1 is less than the threshold and indicator 2 is greater than the threshold: "LA"
[0436] The remaining samples were further classified in the following order.
[0437] (ii) When index 3 ≥ threshold L and index 3 < threshold H: "Def"
[0438] (iii) When indicator 3 is less than threshold value L: “Inh(In3)”
[0439] (iv) When index 2 ≤ threshold and index 3 ≥ threshold H: “Inh(In2)”
[0440] (v) When index 2 > threshold and index 3 ≥ threshold H: "Inh(In1)"
[0441] Table 7 shows the indexes 1 to 3 of each sample, the comparison results between these indexes and the threshold value, and the estimated sample type. According to this estimation standard, LA, Def, and Inh can be distinguished from each other, and Inh can be distinguished in correspondence with titer.
[0442] [Table 7]
[0443]
[0444] 2) Combination of 9:1 mixed sample and 1:9 mixed sample
[0445] Mixed samples with a mixing ratio (sample:NP) of 9:1 and 1:9 (9:1 mixed sample and 1:9 mixed sample, respectively) were prepared, and their respective Tm(X)s were calculated. The following indices 1 and 2 were calculated for the samples (LA, Def, Inh).
[0446] Index 1: FT1 of 9:1 mixed sample (5)
[0447] Indicator 2: FT6 (95)
[0448] [FT1(X)=[(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))]×100
[0449] FT6(X) = [Tm(X) of 9:1 mixed sample - Tm(X) of 1:9 mixed sample]
[0450] For indicators 1 to 2, the average value and standard deviation (SD) of Def (D-1 to D-8) are calculated. For indicator 1, the threshold value, i.e., the average value + 4SD, is used. For indicator 2, the threshold value L, i.e., the average value + 2SD, and the threshold value H, i.e., the average value + 6SD, are used. The calculated indicators 1 to 2 for each test sample are shown in Fig.16 A and B, and also plotting the index 2 of Inh against the potency in Fig.16 C. Fig.16 The dashed line in A represents the threshold value, Fig.16 The dashed lines in B and C represent the threshold L, and the long dashed lines represent the threshold H.
[0451] The indicators 1 and 2 are compared with the threshold value, and based on the comparison result, the sample type of the sample to be tested is estimated according to the following criteria.
[0452] <Estimation criteria>
[0453] (i) Indicator 1 > threshold: "LA"
[0454] The remaining samples were further classified in the following order.
[0455] (ii) Index 2 < Threshold L: "Def"
[0456] (iii) When index 2 > threshold H: "Inh(In1)"
[0457] (iv) When indicator 2 ≤ threshold H: “Inh(In2)”
[0458] Table 8 shows the indicators 1 to 2 of each sample, the comparison results of these indicators and the threshold value, and the inferred sample type. According to this inference standard, LA can be distinguished from other sample types (Def and Inh), and Def can also be accurately distinguished. For Inh, high-titer Inh (In1; I-6 to I-9) with a titer of 46 or more and medium-titer Inh (In2; I-4, I-5) with a titer of 18 or more and less than 46 can be distinguished. On the other hand, low-titer Inh (I-1 to I-3) with a titer of 5 or less can be distinguished from Def.
[0459] [Table 8]
[0460]
[0461] Example 6
[0462] The following indices 1 to 4 are calculated for the test sample (LA, Def, Inh). A mixed sample having a mixing ratio (test sample: NP) of 1:1 is used for the calculation of Tm(X).
[0463] Index 1 = FT1 (45)
[0464] Index 2 = FT2 (5)
[0465] Index 3 = FT2 (45)
[0466] Index 4 = FT2(45) - FT2(5)
[0467] [FT1(X)=(Tm(X)-Tn(X)) / (Ts(X)-Tn(X))×100
[0468] FT2(X)=(Tm(X) / Tn(X))×100〕
[0469] The average value and standard deviation (SD) of Def (D-1 to D-8) are calculated for indicators 1 to 4. The threshold value is the average value + 4SD for indicator 1 and the average value + 1SD for indicators 2 to 4. The calculated indicators 1 to 4 for each test sample are shown in Fig.17 A to D, and the graphs showing the Inh index 4 plotted against the titer are shown in Fig.17 E. The dashed line in each graph indicates the threshold value.
[0470] The indicators 1 to 4 are compared with the threshold value, and based on the comparison result, the sample type of the sample to be tested is estimated according to the following criteria.
[0471] <Estimation criteria>
[0472] (i) Indicator 1 > threshold: "LA"
[0473] The remaining samples were further classified in the following order.
[0474] (ii) When indicator 2 is less than the threshold and indicator 3 is less than the threshold: "Def"
[0475] (iii) Indicator 4 > threshold: “Inh”
[0476] Indicators 1 to 4 of each sample, the comparison results of these indices and the threshold value, and the estimated sample type are shown in Table 9. According to this estimation standard, LA can be distinguished from other sample types (Def and Inh), and Inh with a titer greater than 5 can be accurately distinguished. On the other hand, Inh with a titer of 5 or less (I-1 to I-3) can be distinguished from Def.
[0477] [Table 9]
[0478]
[0479] Comparative Example
[0480] We attempted to distinguish LA, Def, and Inh using conventional APTT-based indices, namely percentage correction (PC) and Rosner index (RI).
[0481] 1) 1:1 mixed specimen
[0482] The following indices 1 and 2 were calculated for the test sample (LA, Def, Inh) with APTT as T(50). A mixed sample with a mixing ratio (test sample: NP) of 1:1 was used for the calculation of Tm(X).
[0483] Index 1: PC (%) = (Ts (50) - Tm (50)) / (Ts (50) - Tn (50)) × 100
[0484] Index 2: RI (%) = (Tm (50) - Tn (50)) / Ts (50) × 100
[0485] For index 1, the average value of Def (D-1 to D-8) - 4SD is set as the threshold value. For index 2, the average value of Def (D-1 to D-8) + 2SD is set as the threshold value.
[0486] The indicators 1 and 2 of the sample to be tested are shown in Fig.18 A, B, Inh indicators 1, 2 are plotted against potency. Fig.18 C, D. The dotted lines in each figure indicate the threshold. Indicators 1 and 2 are both that although LA shows a different distribution from Def and Inh, the distributions of Def and Inh overlap ( Fig.18 In Inh, the index 1 is distributed in a mountain shape with a titer of 18 as the vertex, and the index 2 is distributed in a J shape with a titer of 18 as the lowest point ( Fig.18 C, D).
[0487] The indexes 1 and 2 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the following criteria.
[0488] <Estimation criteria>
[0489] (i) When indicator 1 is less than the threshold: "LA"
[0490] The remaining samples were further classified in the following order.
[0491] (ii) When indicator 2 ≤ threshold: “Def”
[0492] (iii) Indicator 2 > threshold: “Inh”
[0493] Table 10 shows the indexes 1 and 2 of each sample, the comparison results of these indexes with the threshold value, and the inferred sample type. In this inference standard, LA can be distinguished from other sample types (Def and Inh). However, for Inh, although high-titer samples with a titer of 46 or more can be distinguished, Inh with a titer of less than 46 cannot be distinguished from Def.
[0494] [Table 10]
[0495]
[0496] 2) 9:1 mixed sample
[0497] Using a mixed sample with a mixing ratio (test sample: NP) of 9:1, calculate the indicators 1 and 2 calculated in 1) above. For indicator 1, the average value of Def (D-1 to D-8) -3.5SD is set as the threshold. For indicator 2, the average value of Def (D-1 to D-8) +1.5SD is set as the threshold.
[0498] The indicators 1 and 2 of the sample to be tested are shown in Fig.19 A, B, Inh indicators 1, 2 are plotted against potency. Fig.19 C, D. The dotted lines in each figure represent the threshold. For index 1, although LA is distributed below Def and Inh, the distributions of Def and Inh overlap ( Fig.19 A). For indicator 2, the distributions of LA and Inh, and Def and Inh overlap. ( Fig.19 B). In Inh, the index 1 is distributed in a mountain shape with a valence of 18 as the vertex, and the index 2 is distributed in a J shape with a valence of 18 as the lowest point ( Fig.19 C, D).
[0499] The indexes 1 and 2 of each sample to be tested are compared with the threshold value, and based on the comparison result, the sample type of the sample to be tested is inferred according to the inference criterion of 1) above. The indexes 1 and 2 of each sample to be tested, the comparison results of these indexes with the threshold value, and the inferred sample type are shown in Table 11. In this inference criterion, LA can be distinguished from other sample types (Def and Inh), but for Inh, as in the case of the 1:1 mixed sample (Table 10), although high-titer samples with a titer of 46 or more can be distinguished, Inh with a titer of less than 46 cannot be distinguished from Def.
[0500] [Table 11]
[0501]
[0502] 3) 1:9 mixed specimen
[0503] Using a mixed sample with a mixing ratio (test sample: NP) of 1:9, calculate the indicators 1 and 2 calculated in 1) above. For indicator 1, the average value of Def (D-1 to D-8) - 4SD is set as the threshold. For indicator 2, the average value of Def (D-1 to D-8) + 2.5SD is set as the threshold.
[0504] The indicators 1 and 2 of the sample to be tested are shown in Fig. 20 A, B, Inh indicators 1, 2 are plotted against potency. Fig. 20 C, D. The dotted lines in each figure indicate the threshold. Indicators 1 and 2 are that LA shows a distribution different from Def and Inh, but the distributions of Def and Inh overlap ( Fig. 20 In Inh, the index 1 is distributed in a mountain shape with a titer of 26 as the vertex, and the index 2 is distributed in a J shape with a titer of 18 as the lowest point ( Fig. 20 C, D).
[0505] The indexes 1 and 2 of each sample are compared with the threshold value, and based on the comparison result, the sample type of the sample is estimated according to the estimation criterion of 1) above.
[0506] Table 12 shows the indexes 1 and 2 of each sample, the comparison results of these indexes and the threshold value, and the inferred sample type. In this inference standard, for LA, although only one sample (L-2) was inferred as Def, the others could be distinguished from Def and Inh. For Inh, only high-titer samples with a titer of 92 or more could be distinguished, and Inh with a titer of less than 92 could not be distinguished from Def.
[0507] [Table 12]
[0508]
Claims
1. A method for inferring factors for prolonging coagulation time, comprising the following steps: 1) Get Tm(X) and Tn(X), 2) Infer the factors that prolong the coagulation time of the specimen S based on Tm(X), in, Tm(X) represents the measurement point or time at which the coagulation reaction curve of the specimen M reaches X% of the coagulation reaction end point Em. Tn(X) represents the measurement point or time at which the coagulation reaction curve of the specimen N reaches X% of the coagulation reaction end point En, Em is the coagulation reaction end point in the coagulation reaction curve of the specimen M, En is the coagulation reaction end point in the coagulation reaction curve of specimen N, The sample S is a blood sample with a prolonged coagulation time. The sample N is a normal blood sample. The sample M is a mixed sample of the sample S and the sample N. X is greater than 0 and less than 100.
2. The method according to claim 1, wherein: The above 1) further comprises the following steps: detecting the coagulation reaction end point Es in the coagulation reaction curve of the sample S, and obtaining Ts(X) based on Es, Ts(X) represents the measurement point or time at which the coagulation reaction curve of the sample S reaches X% of Es.
3. The method according to claim 2, wherein: Described 2) comprises the following steps: (i) a step of calculating one or more indices Rj, wherein j ≥ 1, the indices Rj are calculated based on at least one selected from Ts(X), Tm(X) and Tn(X), and at least one of the indices Rj is calculated based on at least Tm(X); (ii) a step of comparing the index Rj with a threshold value Tj; (iii) a step of inferring a factor that prolongs the coagulation time of the sample S based on the comparison result; The factors that prolong the clotting time include positive lupus anticoagulant, coagulation factor deficiency, or positive coagulation factor inhibitor.
4. The method according to claim 2, wherein: The 2) step comprises the following steps: Calculate at least one index selected from the following R1 to R8, R1 is an index that reflects the ratio between the difference between Tm(X) and Tn(X) and the difference between Ts(X) and Tn(X) under a specific X. R2 is an index that indicates the amount of change in R1(X) within a specific X range. R3 is an index reflecting the ratio of the change in Tm(X) to the change in Tn(X) in a specific X range. R4 is an index reflecting the relative change rate of T(X) of the sample S or the sample M in a specific range of X. R5 is an index reflecting the amount of change in Tm(X) within a specific X range. R6 is an index reflecting the difference in Tm(X) between the samples M having different mixing ratios of the sample S and the sample N. R7 is an index reflecting the ratio of Tm(X) to Tn(X) at a specific X. R8 is an index indicating the amount of change of R7(X) in a specific X range; The factor that prolongs the coagulation time of the sample S is estimated using the calculated index.
5. The method according to claim 2, wherein: The 2) step comprises the following steps: Calculate the following indicators: R1(Xa)=[(Tm(Xa)-Tn(Xa)) / (Ts(Xa)-Tn(Xa))] Wherein, Xa=5-100; When R1(Xa) is higher than the threshold value T1, the sample S is inferred to be lupus anticoagulant-positive, and in other cases, the sample S is inferred to be coagulation factor-deficient or coagulation factor inhibitor-positive.
6. The method according to claim 2, wherein: The 2) step comprises the following steps: Calculate the following indicators: R4s(Xx,Xy,Xz)=[(Ts(Xx)-Ts(Xy)) / Ts(Xz)] R4m(Xx,Xy,Xz)=[(Tm(Xx)-Tm(Xy)) / Tm(Xz)] Wherein, Xx=5-30, Xy=10-95 and Xz=5-95, or, Xx=45-70, Xy=10-45 and Xz=5-95, and Xx≠Xy; A threshold value T4s for R4s and a threshold value T4m for R4m are set. When R4s of the sample S is lower than the threshold value T4s and R4m is higher than the threshold value T4m, the sample S is inferred to be positive for lupus anticoagulant.
7. The method according to claim 5 or 6, wherein: The following steps are included: For the sample S that was not inferred to be lupus anticoagulant-positive, the following indices were calculated: R2(Xb,Xc)=[R1(Xb)-R1(Xc)], Wherein, Xb=5-55, Xc=10-95, Xb≠Xc; If R2(Xb, Xc) is higher than the threshold value T2, the sample S is inferred to be positive for the coagulation factor inhibitor, and if R2(Xb, Xc) is lower than the threshold value T2, the sample S is judged to be deficient in the coagulation factor.
8. The method according to claim 7, wherein: The following steps are included: For the sample S estimated to be deficient in coagulation factors, the following indexes were calculated: R3 (Xd, Xe) = [Tm (Xd) - Tm (Xe)] / [ Tn ( If R3(Xd, Xe) is lower than the threshold value T3, the sample S is inferred to be positive for the coagulation factor inhibitor.
9. The method according to claim 7, wherein: The following steps are included: For the sample S inferred to be deficient in coagulation factors, when the index R3 (Xd, Xe) is lower than the threshold value T3L, the sample S is inferred to be positive for the coagulation factor inhibitor; and For the sample S inferred to be positive for the coagulation factor inhibitor, when R3(Xd, Xe) is higher than the threshold value T3H, the sample S is inferred to be a coagulation factor inhibitor-positive sample with a high inhibitor titer. For the sample S inferred to be positive for the coagulation factor inhibitor, when R3(Xd, Xe) is between the threshold values T3L and T3H, the sample S is inferred to be a coagulation factor inhibitor-positive sample with an intermediate inhibitor titer. in, R3(Xd,Xe)=[Tm(Xd)-Tm(Xe)] / [Tn(Xd)-Tn(Xe)] Here, T3L<T3H.
10. The method according to claim 7, wherein: The following steps are included: For the sample S estimated to be positive for the coagulation factor inhibitor, the following indexes were calculated: R1(Xa')=[(Tm(Xa')-Tn(Xa')) / (Ts(Xa')-Tn(Xa'))]where, Xa'=5~80; When R1(Xa') is higher than the threshold value T1', the sample S is estimated to be a coagulation factor inhibitor-positive sample having a high inhibitor titer.
11. The method according to claim 5 or 6, wherein: The following steps are included: For the sample S that was not inferred to be lupus anticoagulant-positive, the following indexes were calculated: R5(Xb,Xc)=[Tm(Xc)-Tm(Xb)] Wherein, Xb=5-35, Xc=20-95, Xb<Xc; When R5(Xb, Xc) is higher than the threshold value T5L and lower than the threshold value T5H, the sample S is inferred to be deficient in coagulation factors, and in other cases, the sample S is inferred to be positive for coagulation factor inhibitors, where T5L<T5H.
12. The method according to claim 11, wherein: The method comprises the following steps: for the sample S inferred to be positive for the coagulation factor inhibitor, when R5(Xb, Xc) is lower than the threshold value T5L, the sample S is inferred to be a positive sample for the coagulation factor inhibitor with a low inhibitor titer; or, for the sample S inferred to be positive for the coagulation factor inhibitor, when R5(Xb, Xc) is higher than the threshold value T5H, the sample S is inferred to be a positive sample for the coagulation factor inhibitor with a higher inhibitor titer.
13. The method according to claim 5 or 6, wherein: The following steps are included: For the sample S that was not inferred to be lupus anticoagulant-positive, the following indices were calculated: R7(Xb)=[Tm(Xb) / Tn(Xb)] R7(Xb')=[Tm(Xb') / Tn(Xb')] R8(Xb,Xb')=[R7(Xb)-R7(Xb')] Wherein, Xb=5-95, Xb'=5-95, Xb≠Xb'; When R7(Xb) is lower than threshold T7 and R7(Xb') is lower than threshold T7', the sample S is estimated to be deficient in coagulation factors, and when R8(Xb, Xb') is higher than threshold T8, the sample S is estimated to be positive for coagulation factor inhibitors.
14. The method according to claim 5 or 6, wherein: Further comprising the following steps: For the sample S that was not judged to be positive for lupus anticoagulant, Tm A (X) and Tm B (X), where Tm A (X) represents the measurement point or time when the coagulation reaction curve of the mixed sample A reaches X% of the coagulation reaction end point Em, Tm B (X) represents the measurement point or time at which the coagulation reaction curve of the mixed specimen B reaches X% of the coagulation reaction end point Em, the mixed specimen A is a mixed specimen in which the volume ratio of the specimen S to the specimen N is 9:1, and the mixed specimen B is a mixed specimen in which the volume ratio of the specimen S to the specimen N is 1:9, and X is greater than 0 and less than 100; Calculate the following indicators: <h2 style=";text-align:left;direction:ltr">R6(Xb)=[Tm<h2 style=";text-align:left;direction:ltr"> A <h2 style=";text-align:left;direction:ltr"> (Xb)-Tm<h2 style=";text-align:left;direction:ltr"> B <h2 style=";text-align:left;direction:ltr"> (Xb)] Wherein, Xb=35-95; When R6(Xb) is lower than the threshold value T6, the sample S is estimated to be deficient in coagulation factors, and when R6(Xb) is higher than the threshold value T6, the sample S is estimated to be positive for coagulation factor inhibitors.
15. The method according to claim 14, wherein: The method comprises the step of, for the sample S estimated to be positive for the coagulation factor inhibitor, when R6(Xb) is higher than a threshold value T6', estimating the sample S to be a coagulation factor inhibitor-positive sample having a high inhibitor titer.
16. A program for implementing the method of claim 1 or 2.
17. An apparatus for implementing the method of claim 1 or 2.
